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ABSTRACT
MUSCLE WEAKNESS IN PERSONS WITH MULTIPLE SCLEROSIS
SEPTEMBER 2010
LINDA H. CHUNG, B.S., UNIVERSITY OF OREGON
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Ph.D. Candidate, UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Jane A. Kent-Braun
Skeletal muscle weakness is a problem for people living with Multiple Sclerosis
(MS). Alterations in the central nervous system may be the primary source of muscle
weakness because of the pathophysiology of MS. However, changes in peripheral
mediators of force production may also contribute to muscle weakness in persons with
MS. The main objective of the dissertation was to systematically identify key neural
(motor unit discharge rates, spasticity) and muscular (muscle size, contractile function)
mechanisms of force production that may explain lower isometric strength and dynamic
power in persons with MS compared with age-matched controls. The knee extensor
muscles of the weaker leg were studied, because this muscle group is commonly
affected by MS.
We showed that persons with MS had lower peak isometric torque and dynamic
power compared with controls. Persons with MS had lower motor unit discharge rates,
smaller muscle size, and lower specific power compared with controls. There was no
difference in passive torque (spasticity), specific strength, or maximal rate of force
development between groups. Because differences in isometric strength between
persons with MS and controls were abolished when torque was normalized to muscle
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size, smaller muscle size may explain a large portion of lower isometric strength in
persons with MS. Differences in dynamic power were reduced when peak power was
normalized to muscle size, but remained lower in persons with MS compared with
controls, suggesting that changes in neural factors (e.g., lower motor unit discharge
rates) may explain lower dynamic power in persons with MS. These results suggest
that different mechanisms may contribute to muscle weakness in MS, depending on the
mode of contraction.
Lower motor unit discharge rates and smaller muscle size were identified as key
mechanisms of muscle weakness in persons with MS. Each of these mechanisms has
been shown to improve with resistance training in controls. Thus, this dissertation
provides an evidence-based rationale for resistance training interventions in persons
with MS, to improve isometric strength and power production by increasing motor unit
discharge rates and muscle size.
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PREFACE
Chapters 1 through 4 include the dissertation proposal, as submitted to the
Graduate School in June 2009. In addition to the original proposal, the manuscript of
Study 1 is included (Chapter 5). During a meeting with the dissertation committee in
October 2009, it was decided that Study 2 would no longer be conducted as part of the
dissertation. The reasons for this decision were first, Study 2 could not be undertaken
until the completion of Study 1, which would provide the foundational evidence and
rationale for Study 2; and second, an unreasonable amount of time would be needed to
process and analyze the data from Study 1. Together, these factors rendered Study 2
impractical for inclusion in the dissertation. Rather, it was decided at this meeting to
include a complementary study examining the energy cost of walking in persons with
MS, which was not originally proposed in the dissertation. The manuscript for the
energy cost of walking study is included as Appendix A.
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CHAPTER 1
INTRODUCTION
Multiple Sclerosis
Multiple Sclerosis (MS) is an auto-immune disease affecting the central nervous
system, which includes the brain and spinal cord. It has been estimated that 400,000
people in the United States and 2.5 million people worldwide are living with MS
(National Multiple Sclerosis Society). Although the etiology of MS is unknown,
environmental, infectious, and genetic factors are currently being investigated as
possible causes of MS (54). Diagnosis of MS typically occurs in the second or third
decade of life, and women are twice more likely to develop MS than men. The defining
feature of MS is demyelination of nerves by T-cells, which disrupts the neural
conduction of signals from the central nervous system to effector organs. As a result,
inappropriate neural activity may lead to the onset of symptoms, such as muscle
weakness and loss of postural control.
There are different forms of MS: primary progressive, relapsing-remitting,
secondary progressive, and progressive relapsing. About 20% of initial diagnoses are
primary progressive, which is characterized by a slow, continual worsening of
symptoms. The most common form of initial diagnosis (~80%) is relapsing-remitting;
people with this type of MS experience acute exacerbations of symptoms with periods
of recovery. Within 10 years of diagnosis, about 50% of those who were initially
diagnosed as relapsing-remitting will become secondary progressive, thus, transitioning
to the characteristics of the primary progressive form. A rare form of MS is progressive
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relapsing, which is a combination of the primary progressive and relapsing-remitting
forms.
The diagnosis of MS follows stringent criteria (89), as symptoms may overlap
with other pathologies. Therefore, confirmation of MS may take up to several weeks
from the onset of symptoms. Recent technological advances (i.e., magnetic resonance
imaging with gadolinium enhancement) have allowed for earlier diagnosis of MS (89).
Clinical assessments include spinal taps and evoked potential tests. Spinal taps are
collected samples of cerebrospinal fluid, which is used to determine the number or
pattern of immunoglobulins that indicate the level of the immune response. Evoked
potential tests of the visual, auditory, or somatosensory systems are performed to
measure the magnitude and detection time of an electrical response to a given stimulus,
which provides some insight to the quality of the nervous system.
The demyelination and sclera 1 that define MS can develop anywhere in the
white matter of the central nervous system. For that reason, MS is not limited to a
particular region of the central nervous system. Common symptoms in MS include:
changes in cognitive function, depression, symptomatic fatigue, muscle weakness,
spasticity, dizziness, vertigo, vision problems, bladder and bowel dysfunction, difficulty
in walking, balance problems, abnormal sensations, and pain (National Multiple
Sclerosis Society). These detrimental symptoms may have a major impact on activities
of daily living and overall quality of life in persons with MS.
1

sclera - scarring
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Factors That Influence Muscle Strength and Power
Force generation is the product of a series of events that begins at the motor
cortex of the brain and ends with the cycling of cross-bridges between myofilaments
within the muscle. Impairments at any point along this pathway of force production
may result in a decline in muscle strength2 and power 3 . Central factors of force
production include the recruitment of motor units 4 , rate coding 5 , and adequate
transmission of action potentials 6 to the muscle.
There are a number of peripheral factors that may influence force production.
Processes at the neuromuscular junction, such as the conversion of an electrical signal
(action potential) to a chemical signal (acetylcholine), must be functioning. Excitability
of the muscle membrane and propagation of the action potential along the muscle
membrane and into the transverse-tubules are important in activating the muscle.
Within the muscle, the rate of calcium release from the sarcoplasmic reticulum
modulates the development of force production. Myosin ATPase activity, which is
important in cross-bridge cycling, can affect the shortening velocity of contracting
muscle fibers.
In addition to the aforementioned pathway, strength and power are also
influenced by muscle size. Strength is partially affected by the number of muscle fibers
in parallel, which is represented by muscle cross-sectional area (128). Power is
2

strength – isometric torque
power – product of torque and velocity
4
motor unit – a motor neuron and all of the muscle fibers it innervates
5
rate coding – modulation of motor unit firing rates
6
action potentials – nerve impulses
3

3

partially determined by the number of sarcomeres 7 in series, which affects the maximal
shortening velocity of a muscle fiber (128). Since fiber types differ in contractile
velocity, fiber type distribution within a muscle may also influence power. The order of
fiber types from slowest to fastest is: type I < type IIa < type IIx.
Skeletal Muscle Weakness in Persons with MS
One of the major problems for people with MS is muscle weakness. Lower
extremity muscles are more affected by muscle weakness than upper extremity muscles
in persons with MS (111). The decrease in torque in persons with MS ranges from 16
to 57% during both isometric (18; 80; 82; 83; 111; 113) and dynamic (3; 16; 21; 63; 99;
121) contractions. Reduced torque in persons with MS is often observed during
dynamic contractions at high velocities (3; 45; 63; 99), suggesting the potential for
power loss during high velocity contractions. Power asymmetry 8 in the knee extensors
is also observed in persons with MS (21).
The primary mechanism of muscle weakness may be central in nature and may
be directly affected by the pathophysiology of MS. Demyelination of neuronal axons
may prolong corticomotoneuron conduction time 9 , which is observed in persons with
MS (50; 123). Central activation of the muscle (82; 106; 113) and specific strength 10
(82) are lower in persons with MS (82; 106; 113) and may be a result of lower motor
unit firing rates (33; 106) or poor motor unit recruitment.
7

sarcomeres – the basic contractile units of the muscle fiber
Power asymmetry – one leg being more powerful than the other leg
9
Corticomotoneuron conduction time – the time it takes for the nerve impulse to travel from the brain
to the muscle
10
specific strength – the ratio of maximal voluntary force and the largest muscle cross-sectional area of
the whole muscle
8
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Over time, these central changes may affect peripheral mediators of force
production, such as muscle size, fiber type distribution, contractile function, and
processes at the neuromuscular junction 11 . A decline in muscle cross-sectional area and
altered processes at the neuromuscular junction would impact strength, while shifts in
fiber type distribution and changes in contractile function may affect power.
Spasticity 12 may also contribute to power declines in persons with MS.
There is some evidence that muscle atrophy occurs in persons with MS at both
the whole muscle (57) and muscle fiber (44; 57) levels. However, the decrease in
muscle size is not always observed in persons with MS (16; 82). There are discrepant
findings with regard to fiber type distribution shifts in persons with MS, which may
affect the velocity component of power. Persons with MS show either a higher
percentage of type II fibers and lower percentage of type I fibers (57) or a lower
percentage of type IIa fibers (44) compared to non-MS controls. Studies using
electrical stimulation show that the rate of force development is similar (28; 30) or
lower (82; 113) in persons with MS compared to non-MS controls, suggesting possible
alterations in contractile function that may impede power production. However, at the
muscle fiber level, unloaded shortening velocity (44) and myosin ATPase activity 13
(17) are similar between persons with MS and non-MS controls, indicating that
contractile function is unaltered in persons with MS. Processes at the neuromuscular
junction, such as those that are involved in muscle membrane excitability, may be
11

processes at the neuromuscular junction - these include, but not limited to, neurotransmitter release
from the axon terminal and muscle membrane excitability
12
Spasticity – characterized as “a velocity-dependent resistance to passive stretch by the antagonist
muscle due to the hyperexcitability of the stretch reflex” (64)
13
myosin ATPase activity – enzyme that hydrolyzes ATP to promote the “power stroke” of the myosin
head, which drives cross-bridge cycling
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altered in persons with MS. Prolonged recovery of the compound muscle action
potential magnitude, a measure of muscle membrane excitability, following local curare
treatment is observed in persons with MS (34).
Power deficits in persons with MS may also be explained by spasticity, which is
another major symptom in MS. Spasticity is characterized as “a velocity-dependent
resistance to passive stretch by the antagonist muscle due to the hyperexcitability of the
stretch reflex” 14 (64). Thus, co-activation 15 of the antagonist muscle due to spasticity
may slow the contraction velocity and lower power production of the agonist muscle,
especially during high contraction speeds. Although spasticity is commonly assessed
using subjective tests 16 , very few studies have used quantitative measures of spasticity
in persons with MS (88). Further, the role of spasticity in power production in persons
with MS is not known.
By and large, there are a number of potential mechanisms that contribute to
muscle weakness in persons with MS. The extent to which each of these mechanisms
contributes to overall strength and power declines in persons with MS is not clear.
Certainly, changes in the central mediators of force production may be the primary
mechanisms of muscle weakness in persons with MS. However, there may be
additional contributions from peripheral mediators, such as muscle atrophy and slower
contractile function, that may explain strength and power declines in persons with MS.
14

stretch reflex – muscles spindles that detect changes in muscle length and stretch velocity excite the αmotor neuron of the agonist muscle from which the muscle spindles lie, while inhibiting the α-motor
neuron of the antagonist muscle, thus preventing any further stretching of the muscle (Figure 1.1
describes the circuitry of the stretch reflex)
15
co-activation – as the agonist muscle performs a dynamic contraction, the muscle spindles of the
stretched antagonist muscle becomes activated, and through the stretch reflex, the antagonist muscle
becomes excited while the agonist muscle becomes inhibited
16
subjective tests – Ashworth or Modified Ashworth Scale (11)
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Although central changes may affect peripheral mediators of force production,
peripheral changes may also be a result of lower physical activity levels, which are
observed in persons with MS (57; 81). Further, spasticity of antagonist muscles may
play a role in lower power production in persons with MS. No studies have
systematically examined a variety of potential mechanisms of muscle weakness in the
same group of people with MS.
Postural Control in Persons with MS
Adequate integration and coordination of sensory and motor processes is
important in postural control. The central nervous system receives input from sensory
receptors regarding the body’s position in space via visual, vestibular, proprioceptive,
and tactile cues, and processes this information to appropriately send motor commands
to skeletal muscles, so that balance is maintained. Impairments in sensory reception,
delivery of sensory input to the central nervous system, perception of sensory input in
the brain, appropriate decision-making with regard to motor commands, and delivery of
motor output to skeletal muscle may disrupt postural control.
Balance problems are another major symptom in MS, and there is a high
incidence of falls in ~52% of MS patients (36). About 45% of MS patients use assistive
devices for mobility, particularly those with a progressive type of MS (35). Some of the
postural imbalances in persons with MS may be due, in part, to muscle weakness. Poor
postural control may also be due to lesions that interfere with central processes that
mediate postural control.
Postural control is commonly assessed using subjective measures. Clinical
balance tests challenge patients to maintain postural control for 30 s during semi-
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tandem, tandem, and single-legged stances. These tests reveal that persons with MS
have difficulty with tandem and single leg stances (42; 116). In addition, persons with
MS have poorly controlled balance responses to external perturbations (42). Lower
physical activity levels shown in persons with MS (44; 57) may, partially, be explained
by impairments in postural control.
Ground reaction forces 17 are used to calculate quantitative measures of postural
control, such as the center of pressure variability (130) and time-to-contact (105), in the
anterior-posterior (AP) and medio-lateral (ML) directions. During quiet stance, the net
center of pressure includes the time series of both the active ground reaction forces and
the body’s center of mass projected on the ground (124; 130). The center of pressure
variability is the spatial 18 representation of postural sway over time. The time-tocontact incorporates both spatial and temporal 19 aspects of postural sway, either from
the center of pressure or center of mass, with respect to the base of support 20 over time.
The center of pressure displacement during maximal leaning in the AP direction
is lower in persons with MS compared to non-MS controls (53), indicating smaller
boundary limits of stability in persons with MS. The center of pressure variability in
the AP direction during quiet stance is greater in women with MS compared to women
without MS (21), suggesting poor postural control in women with MS. Conditions
challenging the sensory system (visual, somatosensory, vestibular, proprioception)
show greater postural sway angles (79) and velocities (47) in persons with MS,
especially when relying on the vestibular system alone.
17

ground reaction forces – measured forces, using a force plate, that are equal and opposite of the
forces that are exerted by the feet
18
spatial - displacement
19
temporal – velocity and acceleration
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Although measuring the center of pressure provides some information with
regard to postural control, it does not fully describe the dynamics of postural stability 21
in relation to the base of support. Time-to-contact may be a better measure for studying
postural control in persons with MS, as it provides both temporal and spatial
components of center of mass with respect to the stability limits 22 during a given task.
Time-to-contact is the estimated time a person would take to reach one’s stability limit
before falling. There is limited information about time-to-contact as a measure of
postural sway in persons with MS. Postural studies in the elderly (39; 124) and
Parkinson’s Disease patients (125) show reduced time-to-contact compared to healthy
controls.
Muscle strength is important in postural control (77; 109), especially during
conditions when sensory systems are altered (66). A correlation between muscle
strength and postural sway is observed in Parkinson’s Disease patients (77) and in
stroke patients (66). Power asymmetry in the knee extensors is correlated with center of
pressure variability in persons with MS (21). Bilateral resistance training of the knee
extensors has shown increases in the percentage limits of stability 23 during leaning trials
in multiple directions in middle-aged and elderly adults (109). However, few studies
have looked at the potential improvements in postural stability due to resistance training
in persons with MS. These studies convey the importance of muscle strength and
power on postural control.
20

base of support – area around the feet
dynamics of postural stability – displacement of center of mass, velocity and acceleration of
displacement of the center of mass
22
stability limits – base of support
23
percentage limits of stability – the furthest distance in which the center of gravity traveled from the
mid-point with respect to the theoretical limits of stability computed by the Balance Master System
21
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Overall, postural control is impaired in persons with MS. The examination of
time-to-contact may be useful in understanding the dynamics of postural instability in
persons with MS. The association between postural control and muscle strength needs
further investigation in persons with MS, as these two systems are tightly coupled via
the descending pathway of force production. Because MS presents impairments in
central activation of the muscle, this may also affect postural control.
Strength Training in Persons with MS
Aerobic training programs have resulted in improvements in motor (45; 46) and
cardiorespiratory (97; 102; 108) performance in persons with MS. Interestingly,
spasticity is also ameliorated by an acute bout of unloaded leg cycling in persons with
MS on (73) and off (74) anti-spasticity medication. Although these studies showed
cardiovascular benefits, strength and or power gains from aerobic training are not
always examined.
Resistance training is traditionally used to improve muscle strength directly, as it
targets specific muscle groups. Neural adaptation and muscle hypertrophy are the
primary mechanisms of muscle strength gains during short- and long-term resistance
training, respectively (69). Potential mechanisms of neural adaptation include increased
motor unit recruitment and rate-coding, better activation of synergist muscles, and
reduction in co-activation of antagonist muscles (110).
Few studies have used resistance training programs in persons with MS. Homebased (31) and supervised (127) resistance training programs have produced
improvements in strength, power, and measures of functional mobility (i.e., up-and-go
test, number of steps within 3 minutes, walking speed). However, these studies did not
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include a non-MS control group, which would have provided information regarding the
degree of change in strength, power, and functional mobility in persons with MS
following resistance training. Thus, it is not clear whether the response to resistance
training (i.e., changes in strength, neural adaptation, muscle hypertrophy) may be
blunted by MS.
The underlying mechanisms of strength and power gains in persons with MS are
not known. Because of the pathophysiological nature of MS, it is not clear whether
neural adaptations from 2 weeks of resistance training can occur in people with MS, nor
is it clear how the magnitude of these adaptations in persons with MS may compare to
persons without MS. In persons with no neurological impairment, increased motor unit
firing rates (52) and reduction in co-activation of antagonist muscles (49) have been
observed following resistance training. It is not known if 2 weeks of resistance training
will have a beneficial effect on postural control in persons with MS. If beneficial
effects are observed, this would imply that neural adaptations are enough to improve
balance in persons with MS.
Significance of Dissertation
Inadequate motor performance is a problem in persons with MS. The primary
mechanism of muscle weakness may partially be a compromised central nervous
system, which may further affect secondary mechanisms (i.e., muscle size, contractile
function, etc.). Further, power loss in persons with MS may also be exacerbated by the
presence of spasticity within the muscle. The contribution of all of the potential
mechanisms of muscle weakness is not clear, and an understanding of these
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mechanisms of weakness will be useful in designing appropriate therapeutic
interventions to improve muscle strength and power in persons with MS.
Muscle weakness may partially explain the limitations in performing functional
tasks and maintaining postural control. Indeed, strength and power gains may place
persons with MS further away from disability, so that normal daily activities can be
performed and overall quality of life improved. However, it is not known if the
resistance training response in persons with MS is blunted compared to persons without
MS. This dissertation would provide some evidence with regard to the reversibility of
the detrimental effects of MS using short-term resistance training. Further, benefits of
resistance training may translate to greater postural control in persons with MS,
indicating the importance of neural adaptations on balance.
Study 1: Mechanisms of Muscle Weakness in Persons with MS
The primary aim of this study is to determine the mechanisms of diminished
strength and power in persons with MS. Lower strength in persons with MS may be
attributed to muscle atrophy and lower motor unit firing rates. Spasticity and slow
contractile function may also be important in lower power in persons with MS. An
exploratory aim will examine the contribution of each of the mechanisms of force
production in explaining muscle weakness. The knee extensors (KE) will be examined
in this study, as these muscles are observed to be weak in persons with MS (3; 63; 99;
111; 121) and are important in activities of daily living 24 (15; 21).
Hypothesis 1.1 Maximal voluntary isometric contraction (MVIC) and peak
power (highest power in the power-velocity relationship) of the KE will be lower in
24

activities of daily living – such as stair climbing, rising from a chair, walking, etc.
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persons with MS compared to non-MS controls, indicating muscle weakness in persons
with MS.
Hypothesis 1.2 Motor unit firing rates (needle electromyography; pulses·s-1) of
the vastus lateralis muscle at 50% and 100% MVIC will be lower in persons with MS
than non-MS individuals, suggesting that lower central drive to the muscle may
contribute to strength and power loss.
Hypothesis 1.3 The ratio of voluntary-to-stimulated rate of force development
(% peak torque·ms-1) during an MVIC and specific strength (N·m per cm2) will be
lower in persons with MS compared to non-MS controls, indicating lower
neuromuscular drive to the muscle in persons with MS.
Hypothesis 1.4 Muscle cross-sectional area (from magnetic resonance imaging;
cm2) of the KE will be smaller in persons with MS than non-MS controls, suggesting
that a reduction in muscle size may contribute to strength and power loss.
Hypothesis 1.5 The rate of force development from a stimulated tetanus (%
peak force·ms-1) will be lower in persons with MS than non-MS individuals, suggesting
that contractile function or excitation-contraction coupling may contribute to power
loss.
Hypothesis 1.5 The ratio between passive torque from the hamstrings and
voluntary torque from the KE at high velocities (>120°·s-1) will be greater in persons
with MS than non-MS individuals, suggesting that spasticity contributes to reduced
power during high velocity contractions via co-activation of the antagonist muscle.
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Study 2: Resistance Training in Persons with MS
Aim #1
The primary aim of this study is to determine the effects of 2 weeks of highintensity resistance training (3 times per week) on muscle strength and power, motor
unit discharge rates, and antagonist muscle co-activation in persons with and without
MS. In persons without MS (C), strength gains during short-term training are primarily
due to neural adaptations and not due to muscle hypertrophy (69). As MS is a central
nervous system disease, it may be that neural adaptations (i.e., increased motor unit
discharge rates and lower co-activation of antagonist muscles) are blunted during shortterm resistance training compared to persons without MS. The KE will be examined in
this study.
Hypothesis 1: Increases in KE strength (maximal voluntary isometric
contraction, MVIC; % pre-training) and power (% pre-training) will be greater in C
compared to MS following 2 weeks of resistance training, indicating a blunted response
to resistance training in people with MS.
Hypothesis 2: Maximal motor unit firing rates (pulses·s-1) of the vastus lateralis
muscle during contractions at 100% MVIC will increase in both C and MS following 2
weeks of resistance training, indicating that neural adaptations occurred during
resistance training.
Hypothesis 3: The change in maximal motor unit firing rates of the vastus
lateralis muscle at 100% MVIC following 2 weeks of resistance training will be smaller
in MS compared to C, suggesting blunted responses in motor unit behavior in persons
with MS.
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Hypothesis 4: Co-activation (%) will be lower in both MS and C following 2
weeks of resistance training compared to pre-training levels, suggesting more effective
coordination of neural activation during contractions following training.
Exploratory regression analyses will also be conducted to examine the extent to which
neural adaptations explain changes in strength and power, as well as how strength and
power improvements affect physical function. These results will provide evidence that
short-term resistance training can increase muscle strength and power, as well as show
that the nervous system of persons with MS has the capacity to improve with resistance
training.
Aim #2
The secondary aim of this study is to investigate the effect of resistance training
on postural control during 30 s of quiet and leaning (front, back, left, right) stances and
physical function in persons with MS. Modest, non-significant decreases in postural
sway were reported in persons with MS following a home-based resistance training
program (31). During leaning stances in different directions, limits of stability
increased in persons with no neurological impairment following resistance training
(109). Better balance may translate to improve physical functioning. Since persons
without MS have minimal balance problems and have adequate functional mobility,
changes in postural control and physical function may be greater in MS compared to C.
Hypothesis 2.2.1 The net center of pressure variability (mm) and time-tocontact (s) during 30-second trials of quiet and maximal leaning (front, back, left, right)
will decrease in both C and MS following 2 weeks of resistance training, suggesting
improvements in postural control.

15

Hypothesis 2.2.2 The change in net center of pressure variability and time-tocontact during quiet and maximal leaning (front, back left, right) stances will be greater
in MS compared to C, suggesting greater postural control improvements in persons
with MS compared to non-MS controls following 2 weeks of resistance training.
Hypothesis 2.2.3 The change in 10s rapid foot-tap count, timed 10m walk,
timed up-and-go test, and timed chair rises will be greater in MS compared to C,
suggesting physical function improvements in persons with MS compared to non-MS
controls following 2 weeks of resistance training.
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Figure 1.1
Muscle spindles detect changes in muscle length and velocity. When activated, a
muscle spindle (A) sends an impulse along the Ia afferent nerve (blue) and makes
synaptic connections with the Ia efferent nerve of the agonist muscle (red) and the Ia
inhibitory interneuron (green), which will make synaptic connections with the Ia
efferent nerve of the antagonist muscle (purple). Simply, the stretch reflex excites the
agonist muscle of which the muscle spindle resides and inhibits the antagonist muscle.
Adapted from Human Anatomy and Physiology, Marieb 7th edition.
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CHAPTER 2
LITERATURE REVIEW
Introduction
Muscle weakness is a common problem in MS (National Multiple Sclerosis
Society), and alterations in the physiological processes that underlie voluntary force
production may explain lower strength in persons with MS. Central processes 25 that are
directly affected by the pathophysiology of MS may be the predominating mechanisms
of muscle weakness, which in turn may affect peripheral mediators of force
production 26 and muscle size. Spasticity 27 , another common problem in MS, may also
decrease power through antagonist coactivation of spastic muscles (22). It is not clear
what the major contributors of muscle weakness are in persons with MS.
Muscle weakness may play a role in reduced postural control and physical
function in persons with MS. Short-term resistance training of lower extremity muscles
may provide a means for improving postural control via neural adaptation in persons
with MS. Neural adaptation is shown to contribute to early strength improvements (2
weeks) during a resistance-training program in young adults without MS (69).
However, it is not clear whether neural adaptation is blunted in persons with MS
because of the pathophysiology. In addition, it is unknown whether short-term
resistance training can improve postural control in persons with MS. The aim of this
25

central processes – such as motor unit firing rates, motor unit recruitment, conduction of neural
impulse
26
peripheral mediators of force production – such as neurotransmitter release at the neuromuscular
junction, muscle membrane excitability, propagation of neural impulse along the sarcolemma, calcium
release from the sarcoplasmic reticulum, cross-bridge cycling
27
spasticity - characterized as a velocity-dependent resistance to passive stretch by the antagonist muscle
due to the hyperexcitability of the stretch reflex (64)
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chapter is to present existing literature on potential mechanisms of muscle weakness,
functional mobility, postural control, and resistance training in persons with MS.
Sources of muscle weakness in persons with MS
Central Nervous System
The integrity of myelin sheaths, which insulate neurons of the central nervous
system, is crucial in ensuring adequate delivery of central impulses to effector organs.
Myelin sheaths are layers of phospholipid proteins that surround neuronal axons to
promote quick transmission of action potentials along the nerve via saltatory
conduction. Also, myelin sheaths are dielectric 28 , preventing the electrical current from
leaving the axon – much like the rubber insulation surrounding a copper wire.
A hallmark of MS is the demyelination of neurons. Demyelination affects the
central transmission of afferent (sensory) and efferent (motor) impulses. Conduction
blocks may arise and signal transmission failure may occur due to a reduction in the
safety factor 29 for impulse transmission in demyelinated and lesioned neurons (62; 84).
Clinically, a marked reduction in the amplitude or area of an evoked action potential
may indicate the presence of a conduction block in patients with neuropathological
diseases (23). Axonal damage in demyelinated areas of the neuron has been observed
in persons with MS, using magnetic resonance imaging and magnetic resonance
spectroscopic imaging (78). If severe axonal damage leads to Wallerian degeneration, a
decrease in motor unit size and number may occur, which in turn may decrease force
production. However, no studies have examined motor unit size and number in persons
with MS.
28

dielectric – non-conducting
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Central activation of the muscle plays a key role in voluntary force production.
Voluntary movements are initiated at the motor cortex through the transmission of
impulses along efferent pathways that recruit motor units. The central regulation of
muscle force primarily involves the rate at which central impulses excite the muscle
(i.e., motor unit firing rate, MUFR) and the recruitment of motor units. Intramuscular
electromyography (EMG) is a technique used to record individual motor unit firings via
a needle electrode within the muscle. Compared to non-MS controls, motor unit firing
rates are lower (33; 106) and highly variable (33) in persons with MS. In contrast, the
magnitude of surface EMG activity during force production from 10% to 70% of MVC
is greater in persons with MS compared to non-MS controls (83). It has been suggested
that the increased EMG activity may be due to greater motor unit recruitment as a
compensatory mechanism to overcome lower motor unit discharge rates in persons with
MS (83). Although indirect evidence suggests alterations in motor unit recruitment in
persons with MS, no direct measures of recruitment thresholds have been conducted in
this population.
Transcranial magnetic stimulation is used to examine the transmission of these
impulses by recording the corticomotoneuron conduction time 30 , as well as the
amplitude and area of the impulse that reaches the muscle (motor evoked potential,
MEP). Studies using transcranial magnetic stimulation of the brain show prolonged
corticomotoneuron conduction time (43; 123) and lower MEP amplitude and area (43)
in persons with MS compared to non-MS controls. Abnormalities in MEP amplitude
and area are shown to be more frequent in MS patients with higher disability (Expanded
29

safety factor – the difference between the threshold and peak amplitude of an action potential
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Disability Status Scale score 2-3.5 versus 0-1.5) (43). Bonfiglio et al. (12)
demonstrated that the cortical relay of impulses within the cerebrum may be altered in
persons with MS, in that the prolonged delay in conduction time is primarily due to
alterations in transcortical transmission rather than either afferent and efferent nerve
transmission. The cortical relay time was unrelated to the disease duration of MS (12).
Prolonged absolute and relative refractory periods are also observed in MS patients
(10). Together, these studies suggest that impaired central activation via prolonged
delivery and reduced amplitude of impulses may affect excitation of motor units and
may partially explain reduced force production in persons with MS.
The level of central activation to the muscle can also be examined noninvasively at the periphery by using the following methodologies: central activation
ratio, specific strength, and rate of voluntary force production. Central activation ratio
is the maximal voluntary force relative to the total force produced during the
superimposition of an electrical stimulus or train of stimuli during a maximal voluntary
contraction (MVC) (55). Central activation failure can be determined by observing an
increment in force during the superimposed stimuli on the MVC. Specific strength is
the force per muscle cross-sectional area and allows the determination of muscle
quality, independent of muscle size. Rate of voluntary force development during a
MVC is expressed as the percent change in peak force over time and provides some
indication of neuromuscular drive and contractile properties.
Lower central activation ratio (28; 82; 113) and rate of force development (82)
are observed in persons with MS compared to non-MS controls. There is a modest
30

corticomotoneuron conduction time – the time it takes the impulse to travel from the motor cortex to
the muscle
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decrease in specific strength of the ankle dorsiflexors in persons with MS compared to
non-MS controls (82), but this is not always observed (57). In rats infected with
experimental allergic encephalomyelitis31 , specific strength of the medial gastrocnemius
is lower compared to controls (29). Interestingly, lower specific tension 32 in type I
fibers is observed in persons with MS, suggesting that there may be alterations at the
myofilament level (44). The inconsistent results of specific strength may be a result of
greater variability of specific strength among persons with MS compared to non-MS
controls. It may be that declines in specific strength are more evident in other muscle
groups.
In summary, the pathophysiology of MS has an impact on central factors that
influence the activation of skeletal muscle. Central regulation of force production,
amplitude and area of action potentials, and corticomotoneuron conduction time appear
to be altered in persons with MS compared to non-MS controls. Thus, these changes in
the central nervous system may partially explain muscle weakness in persons with MS.
Neuromuscular Transmission
Neuromuscular transmission involves the translation of a neural signal to a
neurotransmitter signal, which in turn translates into an electrical signal at the muscle.
Specifically, an action potential at the axon terminal causes the release of acetylcholine
that crosses the synaptic cleft and binds to receptors at the motor end plate. This causes
depolarization of the muscle membrane, and if depolarization reaches a threshold, it will
generate an action potential that will propagate along the sarcolemma and into the
31
32

experimental allergic encephalomyelitis – animal model for multiple sclerosis
specific tension – force produced by a single muscle fiber
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transverse-tubules. Failure in any of the aforementioned events could inhibit force
production.
Amplitude of evoked potentials at the ulnar nerve during a short train of stimuli
is lower in MS patients compared to non-MS controls (94), indicating some alteration in
neuromuscular transmission. Evoked potential amplitudes following administration of
anticholinesterase therapy, which minimizes the breakdown of acetylcholine in the
synaptic cleft, are improved in persons with MS (94), suggesting that neurotransmitter
release or its effect on receptors is impaired. Following local treatment of curare 33 ,
recovery of evoked potential amplitudes is slower in people with MS compared to
controls (34), signifying that impairments in neuromuscular transmission may be due to
alterations at the receptor level of the motor end plate. However, persons with MS with
spasticity show minimal depression of the H-reflex response following a slow stretch of
the soleus muscle, as well as greater facilitation of the soleus H-reflex response
compared to controls, indicating decreased presynaptic inhibition (85). Collectively,
these studies show that neuromuscular transmission is changed in persons with MS and
could affect force production.
Muscle Size
Muscle size is important in strength and power production. Both number and
area of muscle fibers contribute to overall force production. Declines in whole muscle
(57) and single muscle fiber (44; 57) cross-sectional area (CSA) are observed in persons
with MS. However, size differences at the whole muscle (82) and fiber level (16) are
not always observed in persons with MS. These discrepancies may be explained by
33

curare - temporarily blocks nicotinic acetylcholine receptors on the motor end plate
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increased data variability in persons with MS, which may be, in part, due to different
degrees of disability and physical activity levels.
The distribution of slow- and fast-twitch fibers may play a role in the velocity
component of power production, as fast-twitch fibers have greater shortening velocity
than slow-twitch fibers. Using the myosin ATPase staining technique, a higher
percentage of type IIa fibers and a lower percentage of type I fibers in the tibialis
anterior muscles were observed in MS patients compared to controls (57). In contrast,
when fiber type distribution is determined by gel electrophoresis and silver-staining
techniques, MS patients had a lower distribution of type IIa myosin heavy chain (MHC)
isoform (44) and greater distribution of type I/IIa/IIx MHC isoforms in MS (16) in the
vastus lateralis muscle. These discrepant results may be due to the different muscles
studied and the analytical approaches used in identifying fiber types. Nevertheless,
there appears to be a shift towards slow-twitch fibers, as well as a greater percentage of
hybrid fibers in persons with MS.
The unloaded shortening velocity of type I and type IIa fibers (44) and the
myosin ATPase activity for each fiber type (17) were similar between persons with MS
and non-MS controls. These data suggest that the rate of cross-bridge cycling is
unaltered in persons with MS. Interestingly, Garner et al. (44) found that specific
tension was lower in type I, but not type IIa, fibers in persons with MS, suggesting that
there may be an alteration in the number of cross-bridges or force per cross-bridge in
type I fibers.
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Contractile Function
Contractile function during voluntary contractions is influenced by central 34 and
peripheral 35 factors. As described earlier, changes in central activation occur in persons
with MS, and these central changes may bring on a cascade of changes within the
muscle. Some studies examining contractile function in the periphery indicate lower
rates of force development (113) and slowed force relaxation (82; 113) during
electrically stimulated contractions in persons with MS, while other studies do not (28;
30). There is a leftward shift in the torque-velocity relationship in lower extremity
muscles (82) but not in upper extremity muscles (30) in persons with MS compared to
non-MS controls, suggesting a slower muscle profile in muscles that work against
gravity.
Contractile velocity, important in power 36 production, may be altered in persons
with MS. Spasticity, a common symptom in MS, may impede high contractile velocity
due to the hyperexcitability of the stretch reflex (see Spasticity). At the muscle fiber
level, spastic muscles have shorter fiber lengths compared to non-spastic muscles (41),
signifying a lower number of sarcomeres in series, which would affect contractile
velocity. Increased muscle stiffness 37 is also observed at the whole muscle (114) and
muscle fiber (41) levels. Thus, muscle stiffness may play a role in lower power
production due to the increased difficulty to generate fast contractile velocities.
34

central – i.e., motor unit discharge rates
peripheral – i.e., fiber-type distribution, calcium kinetics, fiber length (number of sarcomeres in
series)
36
power – product of torque and velocity
37
stiffness - resistance to passive movement that may be due to non-reflex mechanisms
35
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Spasticity
Spasticity is defined as a “motor disorder characterized by a velocity-dependent
increase in tonic stretch reflexes (muscle tone) due to the hyperexcitability of the stretch
reflex, as one component of the upper motor neuron syndrome” (64). The stretch reflex
arc encompasses the muscle spindle, the afferent nerve to the spinal cord, and the
disynaptic connections to the Ia efferent nerve of the agonist muscle and the Ia
inhibitory interneuron (which will make a synaptic connection with the Ia efferent nerve
of the antagonist muscle). Simply, the stretch reflex excites the agonist muscle (the
muscle that is being stretched) while inhibiting the antagonist muscle. The mechanism
of spasticity is still debated, but the hyperexcitability of the stretch reflex may be due to
dis-inhibition at the presynapse (e.g., diminished neurotransmitter release to the Ia
motor neuron) and or reduced disynaptic reciprocal Ia inhibition (e.g., lower inhibition
of the antagonist muscle) (68; 86).
A common clinical assessment of spasticity is the Ashworth or modified
Ashworth scale (11). In these techniques, clinicians manually move the limb segments
and make judgments based on how resistant the joint movement is. The subjective
nature of these tests relies heavily on clinical experience. And it is difficult to discern
what is mediating increased passive resistance, structural (non-reflex) or neural (reflex)
alterations.
Quantitative methods using biomechanical and or electrophysiological
instruments have been developed to improve measures of spasticity in patients. Passive
torque (dynamometer), oscillation decay (pendulum test), H-reflex, and stretch reflex
are used as indices of muscle spasticity (9). Passive torque is the torque produced by a
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muscle that is passively stretched by the dynamometer. The pendulum test uses a
goniometer to measure oscillation decay of the knee joint when the relaxed leg is
released from full extension and is allowed to swing freely. The H-reflex is a surrogate
measure of motor neuron excitability. By electrically-stimulating the nerve, the
maximal amplitude of the H-wave can be determined using surface electromyography
(EMG). The stretch reflex is the EMG signal obtained in response to the stretching of
the muscle. Although there are many ways to quantitatively measure spasticity, there is
no gold standard. The combination of biomechanical and electrophysiological
measurements may provide a more complete evaluation of spasticity by examining the
relationship between stretch velocity and passive torque, and the stretch reflex
threshold, respectively (9).
Numerous studies have used a quantitative approach to assess muscle spasticity
in stroke (4; 98) and spinal cord injury patients (37; 51; 76; 96; 100). Likewise, several
studies have measured spasticity quantitatively in persons with MS (8; 87; 88; 90).
Increased passive torque with increasing speed of passive movement (90) and
dampened oscillation decay (8) at the knee joint are observed in persons with MS.
Increased stretch reflex amplitude with increasing velocity and lower stretch reflex
threshold (i.e., the velocity at which passive torque is detected) of the soleus are
observed in MS patients (87; 88).
Coactivation of the antagonist muscle, as a result of spasticity, during a
voluntary dynamic contraction, may impede power production of the agonist muscle.
Corcos et al. (22) showed a stretch reflex-induced coactivation of the soleus during
dorsiflexion in spastic patients. Musampa et al. (75) also observed stretch reflex-
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induced coactivation of the stretched muscle during elbow extension in stroke patients.
It remains unclear if stretch reflex-induced coactivation plays a role in lower force
production in persons with MS, particularly during high velocity contractions.
Summary: Sources of muscle weakness in persons with MS
Overall, there are many factors that may explain muscle weakness in persons
with MS. These include neural alterations at the central and peripheral levels, changes
in contractile function, muscle atrophy, changes in fiber-type distribution, spasticity,
and coactivation. However, the contribution of each of these factors to muscle strength
and power in persons with MS is not well understood.
Physical Function and Postural Stability in MS
Postural control
Studies have shown that postural control in MS is compromised. Persons with
MS exhibit reduced anterior and posterior center of pressure displacements when
leaning compared to non-MS controls (53). Women with MS have greater center of
pressure variability in the AP direction and greater load asymmetry 38 during quiet
stance compared to non-MS women (21). When one or more sensory systems (visual,
somatosensory, vestibular, proprioception) are perturbed, persons with MS demonstrate
greater postural sway (79). Postural sway velocities in the AP and ML directions
during quiet stance on stable and foam rubber support surfaces are greater in persons
with MS compared to non-MS controls (47).
Postural control may be better measured by time-to-contact, which provides
temporal and spatial information about center of mass relative to the stability boundary,
38

load asymmetry – differences in the ground reaction forces between feet
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than spatial measurements, e.g., center of pressure variability. However, time-tocontact has not been measured in persons with MS. In studies of aging, older adults
exhibit lower time-to-contact in the AP (39; 124) and ML (124) directions during
leaning tasks compared to younger adults. In Parkinson’s Disease patients, time-tocontact in the ML direction is lower compared to healthy controls (125). Time-tocontact may be useful in achieving a comprehensive description of postural control in
persons with MS.
Gait
Physical function and postural stability are important in maintaining activities of
daily living. Persons with MS have slower gait speeds (16; 21; 67; 70; 91; 111; 121),
consisting of shorter stride lengths, decreased cadence, and prolonged double-support
phase during the gait cycle (7; 67). Further, joint angles during the gait cycle are also
altered in minimally-impaired persons with MS (7; 67). Olgiati et al. (93) showed high
energy costs of walking on a treadmill in persons with MS compared to non-MS
controls, which was associated with knee flexion-extension time (their spasticity
measure) in MS patients (91).
In addition to slow walking speeds, women with MS have greater difficulty
initiating gait (104). Minimal displacement of the center of mass (due to a slow anterior
velocity in the anticipatory postural adjustment) and smaller posterior shift in the center
of pressure during gait initiation were observed in women with MS compared to nonMS controls. These data suggest that persons with MS may have a functional strategy
to stay within their stability boundaries 39 until necessary to make the first step (104).
39

stability boundaries – the perimeter of balance
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Effect of muscle strength on postural control and physical function
Muscle strength is important in postural control, which in turn is necessary for
the performance of activities of daily living. Muscle strength and postural control are
linked in that they share the same descending pathway in the nervous system to activate
skeletal muscle. There are very few studies directly examining the role of muscle
weakness in postural control in persons with MS. Chung et al. (21) observed a
correlation between power asymmetry in the knee extensors and center of pressure
variability in persons with MS. In stroke patients, Marigold et al. (66) observed
associations between strength and postural sway when patients had to rely only on their
vestibular system. Correlations between muscle strength and postural sway velocity
during quiet stance are observed in Parkinson’s Disease patients (77). When strength is
improved by bilateral resistance training of the knee extensors, middle-aged and older
adults increased their limits of stability during leaning trials in different directions
(109).
Muscle strength also plays an important role in physical function. Leg power is
predictive of functional mobility and performance in the elderly (5; 26). In MS patients,
gait speed is associated with muscle strength (120), particularly in patients who have
both pyramidal and sensory impairments (121). Recently, knee extensor power
asymmetry was correlated with self-selected, normal and brisk walk times in persons
with MS and non-MS controls, suggesting that asymmetrical weakness may play a role
in physical dysfunction in persons with MS (21).
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Summary: Physical function and postural stability in MS
Overall, physical function and postural control are compromised in persons with
MS. Slow walk speeds, altered gait kinematics, and prolonged gait initiation in MS
patients indicate a functional strategy to minimize the risk of falls. Greater postural
sway in persons with MS suggests difficulties in maintaining balance control. The
inclusion of time-to-contact may give a better description of postural control changes in
persons with MS, as it includes both spatial and temporal components of postural
control. The relationship between muscle strength and postural control needs further
investigation in persons with MS. It is not clear whether strength gains from resistance
training would improve postural control in persons with MS.
Effect of resistance training on motor performance in MS
Resistance training is an effective way of improving strength and power in
targeted muscle groups. There are a number of systemic changes that contribute to
strength gains during long-term resistance training. A classic paper by Moritani and
DeVries (69) showed both training-induced neural and morphological contributions to
strength gains in young, healthy adults, each contributing more to increased strength at
different phases of the resistance training period (Figure 2.1). Neural adaptations
contributed about ~80% during early strength gains at week 2. However, its relative
contribution declined as muscle hypertrophy’s contribution to strength gains increased
after 4 weeks of training. Potential mechanisms of neural adaptation to strength training
are: 1) complete activation of the prime mover by increased motor unit recruitment and
firing rates, and 2) appropriate activation of synergist and antagonist muscles (110).
Motor unit firing rates are increased within the first 2 weeks of resistance training in the
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elderly, who had lower motor unit firing rates compared to young adults at baseline
(52).
There are limitations to Moritani and DeVries work. Neural adaptation was
monitored using integrated, surface EMG signals. Muscle hypertrophy was measured
by taking the largest leg circumference. A better approach would be to measure neural
adaptation using intramuscular EMG for motor unit firing rates and magnetic resonance
imaging (MRI) for muscle cross-sectional area. Nevertheless, Moritani and DeVries
demonstrated that 2 separate mechanisms (neural and muscular components) contribute
to strength gains during resistance training.
There are several studies that have used resistance training in persons with MS.
DeBolt et al. (31) observed increased leg power (sum of both leg extensors) following
an 8 week home-based resistance training (3x/wk for 30min) using weighted vests and
ankle cuffs. White et al. (127) observed strength gains in the knee extensors and
plantarflexors, but not in the knee flexor muscles, following an 8 week resistance
training (2x/wk for 30min) using weight machines (ramp protocol; intensity ranging
from 50% to ~70% MVC). Taylor et al. (118) showed increases in arm and leg press
1RM, following 10 weeks of progressive resistance training (2x/wk for 60min). In
addition to strength or power gains, persons with MS had modest-to-moderate
improvements in physical function, such as decreased time in the up-and-go test (31),
increased number of steps over a 3 min period (127), muscular endurance (118), and
improved gait kinematics 40 (48). It is not clear whether these gains in strength and
power are comparable to non-MS controls, as no non-MS control groups were used in
40

improved gait kinematics – decreased time in the double-support phase and stride length in the gait
cycle
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the above-mentioned studies. It is unknown whether greater gains in strength and
power would have been observed if strength and power were measured using the same
contraction mode as training. Also, potential mechanisms that may explain for
increased strength and power were not examined in these studies.
The underlying mechanisms that contribute to improvements in muscle strength
and power in persons with MS are not known. Neural adaptation may occur through
short-term resistance training and may potentially reverse or slow the detrimental
effects of MS. Häkkinen et al. (49) observed a reduction in coactivation of antagonist
muscles in the elderly to levels of middle-aged controls, following 6 months of
explosive resistance training. Thus, resistance training may lessen coactivation in
persons with MS. However, neural adaptation may be blunted in persons with MS
because of the pathophysiology of MS. Nevertheless, neural adaptations may improve
physical function and postural control in persons with MS by increasing central
activation of the muscle and maximizing force generation.
Summary: Effect of resistance training on motor performance in MS
Strength and power gains can be achieved in persons with MS following
resistance training, however to what extent is unknown. Neural adaptation may impede
negative changes in the nervous system due to MS by increasing motor unit discharge
rates and reducing coactivation. Neural adaptations may also improve postural control
in persons with MS, suggesting a cause and effect relationship between neural input and
postural stability.
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Figure 2.1.
The contribution of neural adaptation and muscle hypertrophy to strength gains changes
over time during resistance training. Neural adaptation plays a greater role in strength
gains early in resistance training (10 reps of dumbbell exercises at 66% RM using
elbow flexors, 2x per day, 3x per week for 8 weeks) , whereas muscle hypertrophy
plays a greater role later in resistance training in young adults. Adapted from Moritani
and DeVries (69).
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CHAPTER 3
PROPOSED METHODS FOR STUDY 1
Participants
Persons with MS and age- and gender-matched non-MS controls will be
recruited from the local community. The inclusion and exclusion criteria are presented
in Table 3.1. Group sizes (n=12 in each group) were estimated from various measures
of interest (see Table 3.2). Due to the lack of information about passive torque in
persons with MS, 14 participants in each group will be studied. This study will be part
of a larger study, funded by the National Multiple Sclerosis Society RG-3974.
Experimental Design
All participants will be screened over the phone prior to their first visit. Visits 1
and 2 will be conducted in the Muscle Physiology Laboratory. During Visit 1,
participants will read and sign the informed consent document prior to their
participation in the study. The following forms will also be completed by the
participant: self-reported EDSS (14); Fatigue Severity Scale (FSS; (60)), Modified
Fatigue Impact Scale (MFIS), Spasticity Scale, Medical History Questionnaire, Physical
Activity Readiness Questionnaire, and Magnetic Resonance Safety Questionnaire.
Height, mass, and physical function 41 will be measured. Familiarization to Biodex
procedures will also take place. Prior to leaving the lab, participants will be given an
accelerometer (GT1M, Actigraph Inc., Pensacola, FL) to wear around their waist for 7
days during waking hours. An activity log will also be provided for participants to
record their daily activities. Accelerometry will be used to match physical activity
41

physical function – measures include 10 s rapid foot-tapping, 10m timed walk at brisk and usual
speeds, timed up-and-go test, timed chair rises (x5)
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levels between MS and non-MS groups, to prevent potential confounding results due to
differences in physical activity.
In Visit 2, participants will perform the Passive Torque, Isometric Contraction,
Dynamic Contraction, and Electrical Stimulation Protocols. In Visit 3, participants will
perform the Intramuscular Electromyography Protocol in the Exercise Neuroscience
Laboratory. Visits 2 and 3 will be separated by 7 days to ensure adequate rest and to
avoid muscular fatigue. The order of which leg is studied first will be randomized and
balanced across groups. To minimize symptomatic fatigue in persons with MS, the
laboratories will be air-conditioned. Visit 4 will take place in the Magnetic Resonance
Imaging (MRI) Center at Cooley Dickinson Hospital, where the participant’s thigh
muscles will be imaged. Table 3.3 summarizes the participant’s schedule for Study 1.
Biodex Isokinetic Dynamometer
Following a 3 minute warm up on a recumbent cycle ergometer (Schwinn 210p;
at no resistance), participants will be seated on the Biodex dynamometer (Biodex
Medical, Shirley, NY, U.S.A.) with the hip angle set at ~90º. The knee joint will be
aligned with the axis of the dynamometer arm. Velcro straps will be used to secure the
leg to the dynamometer arm. Shoulder, waist, and thigh straps will be used to stabilize
the body and leg. Although the KE are the primary muscle groups of interest in this
study, the knee flexors (KF) will also be tested for normalization of EMG responses.
For isometric contractions, the knee angle will be fixed at 90º flexion 42 for knee
extension and knee flexion. In addition, the knee will be fixed at the optimal angle for
knee extension and knee flexion (80º and 40º flexion, respectively) to measure maximal
42

90° knee flexion – relative to full extension (0 degrees)
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force production and maximal EMG activity. For passive and voluntary dynamic knee
extension, the total range of motion (ROM) will be 70°, starting at 90° flexion. Verbal
encouragement will be provided for all contractions. Torque, velocity, position, and
EMG signals will be sampled at 1000 Hz using a customized data acquisition program
in MATLAB software (MathWorks Inc., Natick, MA, U.S.A.). Two surface, bipolar
electromyography (EMG) electrodes will be taped onto the skin above the vastus
lateralis and semimembranosus muscles at sites recommended by Cram et al. (24).
These muscles were chosen to minimize any potential cross-talk that may occur during
muscle activity.
Passive Torque Protocol
Passive torque (N·m) will be measured in each leg for the following velocities
obtained in random order and blocked by group: 10, 30, 60, 90, 120, 150, 180, 210, 240,
270, and 300 °·s-1. Two continuous cycles of knee extension and flexion will be
recorded at each velocity with 5 s rest between directions. The passive torque obtained
at 10 °·s-1 will serve as “baseline” when comparing torques at other velocities. This
comparison will detect any increments in passive torque that occur at higher velocities
due to greater resistance. Torque, position, and velocity data will be recorded. After
correcting for torques due to the moment of inertia, peak torque over the range of
motion will serve as the index of spasticity. Passive-to-voluntary torque ratio during
knee extension will be calculated at each velocity and will be a measure of the effect of
spasticity in the KF on voluntary torque production in the KE.
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Isometric Contraction Protocol
Participants will perform 3 maximal voluntary isometric contractions (MVIC,
N·m; 3-4 s duration) of the KE and KF of each leg, with 2 minutes of rest between
contractions. If the highest MVIC trials are not within 10% of one another, then
additional trials 43 will be performed.
Dynamic Contraction Protocol
Voluntary torque production of the KE will be measured in each leg. Two
consecutive (2-3 s rest between contractions) maximal voluntary contractions will be
performed at each of the following velocities: 30, 60, 90, 120, 150, 180, 210, 240, 270,
and 300 °·s-1. The order of the velocities will be same as the Passive Torque Protocol.
Participants will be instructed to “contract as hard and fast as possible” prior to each
contraction. Further encouragement will be given during the contraction. Once the end
of the ROM is achieved after each contraction, the leg will be moved passively back to
the starting position at a velocity of 60 °·s-1. Participants will have 2 min of rest
between velocities.
Electrical Stimulation Protocol
The knee angle will be set at 90° flexion. Before placing the surface electrodes
over the KE, the skin will be abraded and cleansed with abrasive cream and alcohol, to
improve the signal-to-noise ratio. A constant current stimulator (model DS7A,
Digitimer, Hertfordshire, UK) and two 3” x 5” adhesive pad electrodes, placed at
proximal and distal ends of the KE, will be used to apply a 80 Hz tetanus. The
stimulation intensity will be determined by incrementing the current until 50% of MVIC
43

additional trials – total of 6 trials
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is achieved. Then, 3 tetanic trials will be performed with 2 min of rest between trials.
This protocol will be conducted on KE of both legs.
Intramuscular EMG Protocol
Motor unit firing rates will be collected in the Exercise Neuroscience
Laboratory. Participants will be seated upright with hip and knee angle fixed at ~90°.
A heavy-duty Velcro strap will be wrapped around the waist to stabilize the body. A
Velcro strap will be used to secure the ankle to a force transducer (Interface SM-250,
Scottsdale, AZ).
Participants will perform 3 MVICs of KE, separated by 2 min, with visual
feedback of their force production on a computer screen. If the MVICs are not within
10% of each other, additional MVICs will be performed. Then, participants will briefly
practice achieving 50% MVIC.
Once peak MVIC is determined, the skin over the knee cap and belly of the
vastus lateralis will be cleansed with alcohol. A stainless steel ground electrode will be
taped to the knee cap. Then, a sterilized, four-wire needle electrode will be inserted into
the belly of the vastus lateralis to record intramuscular EMG activity. This electrode
consists of a 27-gauge stainless steel cannula, which houses a square array of four 50
µm-diameter platinum-iridium wires, and provides three recording channels of motor
unit activity. The electrodes will be connected to a Dantec Clinical Electromyograph
(Dantec Counterpoint, Dantec Electronik Medicinsk, Skovlunde, Denmark) where the
intramuscular EMG signals will be displayed on a digital oscilloscope. Analog signals
from the EMG electrodes will be bandpass filtered (1-10 kHz) and amplified (mV/D) in
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the Dantec Clinical Electromyograph. Signals from the Dantec and force transducer
will be acquired at 25.6 kHz.
After ensuring the subject’s comfort, the subject will be asked to contract their
KE at 10 to 30% of MVIC to verify good placement of the needle electrode by viewing
all 3 channels of motor unit action potentials. If required, a slight adjustment to the
location of the electrode will be made to obtain clear recordings of motor unit action
potentials.
Prior to contraction, participants will be instructed “to contract as hard as they
can” until they are cued to relax. Participants will perform a 5 s MVIC with 2 min of
rest between trials. Slight adjustments of the electrode will be performed between trials
to obtain clear recordings of motor unit action potentials, as well as to sample different
motor units. After achieving 3 good trials of clear recordings, participants will be asked
to perform 50% MVIC (using visual feedback of their force production) for 8-10 s, with
2 minutes of rest between trials. Again, small manipulations of the needle electrode
will be made between recordings, and 3 good trials will be achieved before ending the
protocol.
Magnetic Resonance Imaging (MRI) Protocol
Participants will visit the MRI Center at Cooley Dickinson Hospital. All
participants will be screened with a Magnetic Resonance Safety Questionnaire prior to
entry into the magnet room. Proton MRI will be performed using a 1.5 Tesla wholebody system (General Electric Company). Participants will be supine on a bed, and a
phase-array coil will be wrapped around the thigh. The bed will then be moved into the
bore of the magnet so that the mid-thigh is positioned at the isocenter. Forty-six T1-
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weighted serial transverse images will be obtained. The following parameters will be
used in acquiring serial images: 256 x 256 matrix, field of view of 300mm, 2 averages,
and slice thickness of 6mm with no gaps. Participants will have both legs imaged.
Data Processing
All participants will be coded by the investigator prior to data collection.
Following each participant’s completion of the study, identifiable paperwork will be
removed from the participant folder. Unless specified otherwise, all data processing
will be conducted using custom-designed programs in MATLAB.
Strength and Power
All torque data will be corrected for the effects of gravity to account for the
weight of the limb and apparatus. The highest MVIC will be used for maximal strength
and to calculate specific strength (N·m·cm-2). Power (W) will be calculated as the
product of torque and velocity. Peak power will be determined by taking the highest
power calculated from all velocities. Torque and power pilot data from a non-MS male
participant are presented in Figure 3.1.
Neuromuscular Drive
Acquired signals of motor unit action potentials will be up-sampled to 51.2 kHz.
Simultaneously acquired force data will be down-sampled to 50 Hz. Individual motor
unit action potentials will be identified using customized spike recognition algorithm
software, which is an automatic spike detection system that makes use of the discharge
history and template-matching for identification. Following auto-identification of
motor units, manual identification will be performed to resolve superpositioned motor
units and to correct for mis-identified motor units. The interpulse interval (s) between
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consecutive firings of a given motor unit will be determined and averaged during the
peak plateau of a MVIC. The firing rate (pulses per second, pps) of a given motor unit
will be calculated by taking the inverse of the interpulse interval. The mean firing rates
of all motor units per contraction will be calculated 44 . The maximum and mean firing
rates during 50% and 100% MVIC for each participant will be determined. Pilot data
from a non-MS male participant are presented in Figure 3.2.
Specific force will be calculated by normalizing MVIC with muscle crosssectional area (mCSA), which will be determined by MRI. For each cross-sectional
slice, the signal intensity thresholds will be determined to discriminate contractile from
non-contractile tissue. The 3 largest consecutive knee extensor mCSAs will be
analyzed twice by manually outlining the knee extensors, and then, averaged. As
another secondary measure of neuromuscular drive, we will use the ratio of voluntaryto-stimulated rate of force development.
Contractile Function
The rate of force development during a 50 Hz tetanus will be expressed as
percent of peak force per ms and will be a measure of contractile speed. In addition, the
velocity that results in 50% of isometric force will be used to determine changes in
contractile function, represented by shifts in the voluntary torque-velocity relationship
in persons with MS compared to non-MS controls.
Spasticity and Coactivation of Spastic Antagonist Muscles
Peak passive torque (N.m) will be determined at each velocity following
moment of inertia correction. The lowest velocity that produces passive torque and
44

firing rates of all motor units … will be calculated – doublets and interpulse interval> 200 ms will
not be included in the calculation of motor unit firing rates
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EMG activity together will serve as the spasticity threshold. A linear envelope will be
applied to the surface EMG data and the area of linear envelope will be used as a
measure of muscle activity. The ratio of normalized KF and KE EMG activity will be
used as a measure of coactivation. Pilot data of torque and surface EMG during
voluntary dynamic knee extension from a non-MS male participant are presented in
Figure 3.3.
Statistical Analyses
All statistical analyses will be performed using Statistical Analysis Software
(SAS Institute Inc., version 8.0, Cary, NC). To characterize our participants, unpaired ttests will be used to detect differences between persons with MS and non-MS controls
in: age, height, mass, FSS, MFIS, spasticity scale, foot-tap counts, walk times, timed
up-and-go test, timed chair rises, MVIC, peak power, specific strength, spasticity
threshold, velocities at 50% MVIC, and total accelerometer counts. A 2-way repeated
measures analysis of variance (rmANOVA; group x velocity) will be used to detect
differences in passive torque between groups over the range of velocities.
For Hypotheses 1.1 to 1.3, an unpaired t-test will be used to detect group
differences in muscle cross-sectional area, motor unit firing rates during 50% and 100%
MVIC, ratio of voluntary-to-stimulated rate of force development, and stimulated rate
of force development. For Hypothesis 1.4, a 2-way rmANOVA (group x velocity) will
be tested on passive-to-voluntary torque ratio to detect differences across groups over a
range of velocities. In the case of significant interactions, post hoc analyses (Tukey’s)
will be performed to determine where differences occur. To explore which mechanisms
may explain muscle strength (i.e., mCSA, motor unit firing rates) and power (i.e.,
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mCSA, motor unit firing rates, passive-to-voluntary torque ratio, contractile properties)
decrements in persons with MS, multiple linear regression analyses will be performed.
The level of significance will be set at p ≤ 0.05. Data will be expressed as mean
± SD. Precise p-values and the 95% confidence interval for differences between groups
will be reported, where appropriate.
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Table 3.1.
Inclusion and exclusion criteria.
Inclusion criteria for



Clinically verified MS

all persons with MS



Self-reported Expanded Disability Status Score (EDSS)
between 2 and 6



No exacerbations in the past 6 months

Inclusion criteria for



Are between the ages of 21 and 60 years

all participants



Are sedentary to recreationally-active

Exclusion criteria for



Have a metabolic, non-MS neurologic, cardiovascular, or
other disease

all participants


Taking any medications (other than for MS) that may
affect muscle function



Are pregnant



Have a cognitive impairment or a mental disorder that
precludes following protocol instructions



Have arthritis in the lower extremities



Have a history of dyspnea, cramping, or light-headedness
during exercise



Are currently smokers or stopped smoking within the past
6 months
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Table 3.2.
Sample size estimates were calculated using unpaired t-tests (power set at 80% and
significance level set at 0.05) on variables of interest in Study 1. SD = standard
deviation. KE = knee extensors. VL = vastus lateralis. DF = dorsiflexors. MVIC =
maximal voluntary isometric contraction. AP COP = center of pressure in the anteriorposterior direction. MUFR = motor unit firing rates. mCSA = muscle cross-sectional
area. RFD = rate of force development. T1/2 = half-time of force relaxation.
Ref.

Variable

Mean of
Non-MS
156

Mean
of MS
92

(121)

KE MVIC (N·m)

(21)

KE power (W)

206

AP COP variability (mm)

4.33
27.9

(106)

Passive KE torque at 120
°/s (N·m)
VL MUFR (pps)

23.8

(57)

DF mCSA (cm2)

(113)

RFD (% peak force·ms-1)

(37)
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Sample size
estimate
7

155

42

12

7.52

1.79

7

8.4

11

13.1

2.6

4

11.1

7.8

1.2

4

1017

846

50

3

46

Mean
of other

38.8
(stroke)

SD

Table 3.3.
Summary of participant’s schedule for Study 1.
Visit

Location

Description

1

Muscle Physiology
Lab – UMass

2

Muscle Physiology
Lab – UMass
Exercise
Neuroscience Lab –
UMass
MRI Center – Cooley
Dickinson Hospital

Paperwork, physical function
assessments, Biodex
Familiarization, accelerometry
Contraction and Electrical
Stimulation protocols
Intramuscular Electromyography

3
4

MRI of thigh muscles
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Approximate
Duration
2 hrs
2.5 hrs
1.5 hrs
1.25 hrs

Figure 3.1.
Torque (top) and power (bottom) data from a non-MS male participant across a range of
velocities.
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Figure 3.2.
Pilot data of the mean and maximum motor unit firing rates at 50% and 100% MVIC
from a non-MS male participant.
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Figure 3.3.
Torque and surface EMG of the VL and SM of 3 consecutive dynamic contractions at
120 °·s-1 (top) from a non-MS male participant. VL = vastus lateralis. SM =
semimembranosus.
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CHAPTER 4
PROPOSED METHODS FOR STUDY 2
Participants
Sample size estimates were determined from DeBolt et al. (31) and Christie and
Kamen (19), which suggested 13 and 10 participants in each group, respectively, to
detect differences in muscle power and motor unit firing rates pre-to-post training at
80% statistical power. Therefore, 10 participants with and 10 without MS will be
recruited from Study 1 and from the local community. All participants will undergo
resistance training in the Muscle Physiology Laboratory. Study 2 will also be a part of
a larger study, funded by the National Multiple Sclerosis Society RG-3974.
Experimental Design
Table 4.1 summarizes the study timeline for each participant. Participants will
come to the laboratories (Muscle Physiology and Exercise Neuroscience Labs) for a
total of 10 visits: a familiarization visit, 2 pre-training visits, 6 resistance training
sessions and 1 post-training visit. With the exception of the intramuscular EMG
protocol, which will be conducted in the Exercise Neuroscience Lab, all procedures will
be performed in the Muscle Physiology Lab.
During Visit 1, participants will read and sign the informed consent document
prior to their participation in the study. Once consent is given, all participants will fill
out the Medical History questionnaire, Physical Activity Readiness questionnaire,
Fatigue Severity Scale (FSS), and Modified Fatigue Impact Scale (MFIS). Persons with
MS will also fill out the self-reported EDSS. Height, body mass, and blood pressure
will be measured. To evaluate physical function, participants will perform 10 s of rapid
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foot-tapping, 10 m timed walk at a brisk and usual paces, timed up-and-go test (8 ft),
and 5 timed chair rises. At the end of Visit 1, participants will become familiar with the
isometric and dynamic contraction protocols on the Biodex isokinetic dynamometer
(Biodex Medical, Shirley, NY, U.S.A.) on both legs, which will determine the weaker
leg that will be used for pre- and post-training measure of intramuscular EMG.
Visit 2 will involve isometric and dynamic contractions with bipolar EMG
electrodes taped over the vastus lateralis and semimembranosus muscles. Visit 3 will
consist of postural control measures and intramuscular EMG. Resistance training will
begin the day after the pre-training measures (Visits 4-9). The first set of maximal
repetitions on the last training visit (Visit 9) will be replaced with the dynamic
contraction protocol, to re-assess the load-power relationship. The day following the
last training session (Visit 10), postural control measures and intramuscular EMG will
be re-assessed. In addition, participants will perform the same physical function
measures as in Visit 1, to determine whether increases in strength and power are
associated with improved physical function. Visits 1 and 2 will be separated by 3 to 7
days to ensure adequate rest prior to pre-training measures.
Biodex Isokinetic Dynamometer
Following a 3-min warm-up on a recumbent cycle ergometer with no resistance
(Schwinn 210p, Nautilis, Inc., Vancouver, WA), participants will be seated on the
Biodex dynamometer with the hip angle set at ~90º. The knee joint will be aligned with
the axis of the dynamometer arm, and Velcro straps will be used to secure the weaker
leg. Shoulder, waist, and thigh straps will also be used to stabilize the body and leg.
The procedures for isometric contractions of the KE and KF, dynamic contractions of
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the KE, and surface EMG electrode placement over the vastus lateralis and
semimembranosus muscles will be the same as in Study 1. Verbal encouragement and
visual force feedback during contractions will be provided to all participants. Analog
signals from the Biodex dynamometer (torque, velocity, position) and EMG electrodes
(Delsys, Boston, MA) will be converted to digital signals (National Instruments
Corporation, Austin, TX) and sampled simultaneously at 2500 Hz using a customized
data acquisition program in MATLAB software (MathWorks Inc., Natick, MA, U.S.A.).
Isometric Contraction Protocol
Participants will perform 3 MVICs (N·m; 3-4 s duration) of the KE and KF,
with 2 min rest between contractions. If the 2 highest MVIC trials within each muscle
group are not within 10% of one another, then additional trials (up to 6 MVICs) will be
performed.
Dynamic Contraction Protocol
Voluntary torque production of the KE will be measured in the non-dominant
leg. Two consecutive (2-3 s rest between contractions) maximal voluntary dynamic
contractions (MVDC) will be performed at each of the following loads: 20, 30, 40, 50,
60, and 70 % MVIC. These velocities were chosen to evaluate peak power from the
load-power relationship for each participant. The order of the velocities will be
randomized across participants and balanced across groups. Once the end of the ROM
is achieved, the leg will be moved passively back to the starting position. Participants
will have 2 min of rest between velocities. The optimal load at which peak power is
produced will be used as the intensity for resistance training.
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Postural Control Protocol
Retroreflective markers will be placed on the participant’s head, trunk, pelvis,
arms and legs for the calculation of whole-body center of mass in 3 dimensions.
Marker triads will also be placed over the upper arms, thighs and calves (Figure 4.1).
Two adjacent force plates (Advanced Mechanical Technology Inc., Watertown, MA)
will be used to record ground reaction forces. Participants will stand with their feet hipwidth apart and each foot placed on its own force plate. Participants will perform 2
trials of quiet stances, each lasting for 30 s. Data will be acquired from a camera
system (Proreflex MCU 240, Qualysis, Gothenburg, Sweden) using Qualisys Track
Manager (Qualysis Medical AB, Gothenburg, Sweden). The analog signals from the
camera and force plates will be sampled at 240 Hz.
Intramuscular EMG Protocol
Maximal motor unit firing rates will be collected in the Exercise Neuroscience
Lab. The procedures will be the same as in Study 1. Only the weaker leg will be
studied.
Resistance Training Protocol
Participants will come to the Muscle Physiology Lab for ~30 min, 3 times per
week for 2 weeks. Both legs will be trained to examine how changes in strength and
power affect physical function after training. At the start of each session, participants
will warm up on a recumbent cycle ergometer for 3 minutes. Then, participants will be
seated on the Biodex dynamometer and will perform 3 MVICs of the KE, with 2 min of
rest between trials. This procedure will allow us to track strength gains during the
course of the training protocol. The intensity of resistance training will be set at an
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optimal load (% MVIC) at which peak power is produced from the load-power
relationship. Participants will perform 3 sets of 10 maximal repetitions at the optimal
load, with 5 min of rest between sets. Participants will be instructed to contract their
muscles rapidly and forcefully against the load imposed by the dynamometer. Verbal
encouragement and torque feedback (light diode box) will be given to each participant
at each training session. Torque, position, and velocity will be recorded during the
training sessions.
Data Processing
All data processing for torque, power, co-activation, motor unit firing rates will
be the same as in Study 1. Visual 3DTM (C-Motion, Inc., Rockville, MD) will be used
to compute the center of pressure (COP) for each foot from ground reaction forces, as
well as whole-body center of mass from marker coordinates. The net center of pressure
represents the whole body center of pressure, calculated as:

⎛
Fzleft
CoPnet = ⎜ CoPleft ⋅
⎜
Fzleft + Fz right
⎝

⎞ ⎛
Fz right
⎟ + ⎜ CoPright ⋅
⎟ ⎜
Fzleft + Fz right
⎠ ⎝

⎞
⎟
⎟
⎠

equation 1

where Fz is the ground reaction force, and left and right refers to the left or right force
plate (130). The center of pressure variability will be the standard deviation of the net
center of pressure over a time series in the AP and ML directions.
Time-to-contact (TtC) of the center of mass in the AP direction will be
calculated by taking the average of the instantaneous distance and velocity of the whole
body center of mass with respect to the stability boundary over time:

TtC( i ) =

d( i )
VCOM ( i )
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equation 2

where d(i) is the instantaneous distance from the whole body center of mass to the AP
stability boundary (defined by the perimeter of the feet) and VCOM(i) is the
instantaneous velocity of the center of mass in the AP direction (125) (Figure 4.2). In
quiet stance, the center of mass would not normally cross the stability boundary.
Therefore, TtC is the predicted time it would take for the center of mass to reach the
stability boundary based on its current position and velocity. Figure 4.3 presents the
time series of TtC from a non-MS male participant.
Statistical Analyses
All analyses will be performed using Statistical Analysis Software (SAS
Institute Inc., version 8.0, Cary, NC). Unpaired t-tests will be used to detect differences
in group characteristics (age, height, body mass, FSS, MFIS, and spasticity scale). To
test the hypotheses, 2-way repeated measures ANOVA (group x time) will be used to
examine the changes from pre- to post-resistance training in: MVIC, peak power,
maximal motor unit firing rates, co-activation, net COP variability, TtC, and physical
function (foot-tap counts, brisk and usual pace walk times, timed up-and-go test, and
timed chair rises). If significant interactions are present, post hoc analyses (Tukey’s)
will be used to determine where significant differences occur. Linear regression
analyses will be performed to determine associations between muscle strength, power,
physical function and postural control.
The level of significance will be set at P ≤ 0.05. Data will be expressed as mean
± SD. Precise p-values and 95% confidence intervals for differences between groups
will be reported, where appropriate.
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Table 4.1.
Summary of participant’s schedule for Study 2. Baseline measures will take place in

Visits 2-3, and post-training testing will take place in Visits 10. During Visit 9, the first
set will be replaced with the dynamic contraction protocol with surface EMG, to reassess load-power relationship.
Visit
1
2
3
3

Location

Description

Muscle
Physiology Lab
Muscle
Physiology Lab

Paperwork, physical function
assessments, Biodex familiarization
Isometric and Dynamic Contraction
protocols plus surface EMG on both
legs
Postural Control protocol

Motor Control
Lab
Exercise
Neuroscience Lab

Intramuscular EMG of vastus
lateralis on weaker leg

Approximate
Duration
1.5 hrs
2.5 hrs
1.25 hrs
1.25 hr

Visits 4-9
2 weeks of resistance training on both legs
3x per week
3 sets of 10 maximal repetitions at optimal load
10
10

Motor Control
Lab
Exercise
Neuroscience Lab

Postural Control protocol

1.25 hrs

Intramuscular EMG of vastus
lateralis on weaker leg

1.25 hr
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Figure 4.1.
For postural control measures, retroreflective markers will be placed on the head, trunk,
pelvis, arms, and legs for calculation of whole body center of mass.
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Figure 4.2.
Adapted from van Wegen et al. (125), this is a pictorial representation of the time-tocontact (TtC) measure. Time-to-contact (TtC) of the center of mass in the AP direction
will be calculated by taking the average of the instantaneous distance (d) and velocity
(v) of the whole body center of mass (COM) with respect to the stability boundary
(solid line around feet) over time.
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Figure 4.3.
Time series of TtC during 60 s of quiet stance from a non-MS male participant.
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MECHANISMS OF MUSCLE WEAKNESS IN PERSONS WITH MULTIPLE
SCLEROSIS
Abstract
The aim of this study was to identify the key contributors to knee extensor
muscle weakness in persons with MS. Lower peak isometric torque (Nm) and power
(W) were shown in MS (n=14; 12 females, 2 males), compared with age-matched
control (n=14; 11 females, 3 males). Smaller fat-free muscle cross-sectional area
(magnetic resonance imaging, cm2; p=0.04) and lower maximal motor unit discharge
rates (p=0.04) in the vastus lateralis were observed in MS compared with control.
Specific strength (Nm·cm-2; p=0.48) was not different across groups, but specific power
(W·cm-2; p=0.05) was lower in MS. These results suggest that smaller muscle size and
lower motor unit discharge rates explain much of the weakness in persons with MS.
Because muscle size accounted for differences in isometric strength, but not entirely for
differences in power, the mechanisms of weakness in MS appear to be contractionmode specific, and include both anatomical and neural mechanisms.
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Introduction
A common symptom of multiple sclerosis (MS), an auto-immune disease of the
central nervous system, is muscle weakness. Lower isometric (18; 80; 82; 83; 111; 113)
and dynamic (3; 16; 21; 63; 99; 121) torque have been shown in persons with MS
compared with non-MS controls. Weakness is particularly evident in the knee extensor
muscles (3; 18; 21; 63; 99; 111; 121). Despite numerous studies on isometric strength
and dynamic power in persons with MS, the mechanisms of MS-related changes in
force production remain unclear.
Muscle weakness in MS may be a direct consequence of changes in the central
nervous system due to demyelination, a defining feature in MS that compromises the
rapid and complete transmission of action potentials to effector organs, such as skeletal
muscle. Investigators have reported central activation failure in persons with MS in the
ankle dorsiflexor (82; 113) and knee extensor (28) muscles. Lower maximal motor unit
discharge rates have been shown in a small group of 4 individuals with MS compared
with controls during a MVIC (106). In other neuromuscular disease patients, lower rate
of force development, normalized to the rate of force development during a stimulated
contraction, was observed compared with controls (59), suggesting alterations in neural
drive during voluntary force production.
Spasticity, another common symptom in MS, may contribute to power deficits
in this population. Spasticity is characterized as “a velocity-dependent resistance to
passive stretch by the antagonist muscle due to the hyperexcitability of the stretch
reflex” (64). That is, co-activation of antagonist muscles due to spasticity may slow
contraction velocity and lower power production of agonist muscles, particularly during
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high contraction velocities. Clinically, spasticity is assessed using the Ashworth or
Modified Ashworth Scales (11). Numerous investigators have used biomechanical and
electrophysiological techniques to quantify spasticity in stroke (4; 98), spinal cord
injury (37; 51; 76; 96; 100), and MS (8; 88; 90). Torque resistance to passive limb (i.e.,
passive torque) movement is one measure of spasticity that is obtained using a
dynamometer. Nuyens et al. (90) observed higher passive torque during knee extension
and knee flexion in persons with MS compared with controls. Spasticity has not been
measured in the context of its potential effect on muscle weakness in MS. Thus, it is
not known whether the degree of spasticity in an antagonist muscle may explain a
portion of lower torque production of the agonist muscle during dynamic contractions in
persons with MS.
Lower fat-free muscle cross-sectional area is observed in persons with MS in the
ankle dorsiflexor muscles (57). In addition, studies have shown lower single fiber
cross-sectional area of ankle dorsiflexor (57) and vastus lateralis (44) muscles in
persons with MS compared with controls. Together, these results suggest that smaller
muscle size is a contributor to muscle weakness in MS. Investigators have reported a
modest decline (82) or no difference (57) in specific strength (force normalized to
muscle size) of the ankle dorsiflexor muscles in individuals with MS compared with
controls, indicating that muscle quality may or may not be reduced. To date, no studies
have examined specific strength and specific power in the knee extensor muscles in
persons with MS.
Alterations in contractile function may limit power (a product of contraction
velocity and torque production), as a slower rate of force development may impede
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contraction velocity. Lower rates of force development during a stimulated contraction
are observed in the ankle dorsiflexor muscles in persons with MS compared with
controls (113). However, others have shown no difference between persons with MS
and controls in the maximal rate of force development in the knee extensor muscles (28;
30). Thus, it is not clear whether lower power may be partially explained by slower
contractile properties.
Indeed, there are a number of potential mechanisms that could contribute to
muscle weakness in persons with MS. The extent to which these mechanisms influence
overall strength and power in persons with MS is not clear. Further, muscle weakness
in MS has been associated with lower physical function (21; 121) and symptomatic
fatigue (21), another significant symptom of MS. These relationships suggest that
muscle weakness has a negative impact on activities of daily living and overall quality
of life in persons with MS.
The aim of this study was to systematically determine the mechanisms of
diminished isometric strength and dynamic power in the knee extensor (KE) muscles of
persons with MS. We hypothesized that, compared with controls, persons with MS
would have 1) lower peak isometric torque and power, 2) lower maximal motor unit
discharge rates in the vastus lateralis muscle, 3) higher passive torque in the knee
flexors (KF) and higher percentage of KF passive-to-KE voluntary torque during highvelocity (>120 °·s-1) contractions, 4) slower voluntary rate of force development (RFD),
5) lower fat-free KE muscle cross-sectional area, 6) lower specific strength and lower
specific power, and 7) slower stimulated RFD. In addition, isometric strength and
power associations with key mechanisms of weakness were explored. Associations
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between isometric strength, power, physical function and symptomatic fatigue were also
explored.
Methods
Study Design
Participants came in for a total of 4 visits, each separated by 3 to 7 days.
Detailed information for each measure is described in the following sections. Briefly,

Visits 1 and 2 were conducted in the Muscle Physiology Laboratory. At Visit 1, signed
informed consent, participant characteristics and measures of symptomatic fatigue were
collected; and familiarization with the Biodex dynamometer (Biodex Medical, Shirley,
NY, U.S.A.) procedures was performed. Isometric strength was measured in each leg to
determine which was weaker. At the end of Visit 1, participants were issued an
accelerometer and instructed in its use. At Visit 2, physical function, muscle strength,
power, spasticity and contractile function were measured on the weaker leg. At Visit 3,
motor unit discharge rates of the vastus lateralis of the weaker leg was measured in the
Exercise Neuroscience Laboratory. At Visit 4, magnetic resonance imaging (MRI) of
the weaker thigh was conducted, in the MRI Center of Cooley Dickinson Hospital.
Group Characteristics
Fourteen persons with MS (12 females, 2 males) and 14 age-matched
individuals without MS (11 females, 3 males) gave signed informed consent, as
approved by the Institutional Review Board at the University of Massachusetts,
Amherst. Participants were recruited from the university and surrounding communities,
as well as through the Central New England Chapter of the National MS Society.
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Participants completed the Spasticity Scale (107), a medical history form, the Physical
Activity Readiness Questionnaire (119), and a magnetic resonance safety questionnaire.
Persons with MS were moderately impaired, as determined by their self-reported
Expanded Disability Status Scale (sEDSS (14)) score of 4.7 ± 1.1 (mean ± SD, range 36). Of the 14 persons with MS, 13 individuals had relapsing-remitting and 1 individual
had the primary-progressive subtype. Medications taken by participants with MS
included [number of individuals]: immuno-modulators [13], anti-depressants [5],
analeptics [4], bladder-control medications [3], muscle relaxants [3], and antihypertensives [2] (see Appendix B), and vitamin D supplements [5]. Of the participants
with MS, 4 indicated having no symptoms of spasticity, 6 had some problems with
spasticity that did not interfere with their activities, 2 had spasticity that forced them to
change some of their activities about once a week, and 2 had problems with spasticity
that forced them to modify their daily activities, based on the Spasticity Scale by Rizzo
et al. (107). Participants with MS were excluded if they had an exacerbation within the
previous 6 months.
All participants were healthy (other than MS-related symptoms), between the
ages of 30 and 60 years, had no cardiovascular, neurological or neuromuscular disease
(other than MS), were free from orthopedic injury in the legs, and were ambulatory.
Sedentary to recreationally-active participants were recruited for both study groups to
minimize differences in physical activity level. Five of the 14 controls were taking the
following medications [number of individuals]: birth control [2], levothyroxine [2], and
prilosec [1].
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Anthropometrics. Height (m) and mass (kg) were recorded, and body mass
index (BMI; kg·m-2) was calculated. Leg length (knee joint axis to lateral malleolus of
fibula) was measured on the tested leg, for calculation of the torque due to inertia (see
Spasticity).

Symptomatic Fatigue. To characterize general fatigue and the impact of fatigue
on quality of life, participants completed the Fatigue Severity Scale (FSS (60)) and the
Modified Fatigue Impact Scale (MFIS; 21-items from Fatigue Impact Scale (38)),
respectively. Scores for the 21-item MFIS were calculated as a sum of all item
responses, whereas the 7-item FSS responses were averaged. Prior to the strength and
power measures, participants were asked to draw a vertical line on the Visual Analog
Fatigue Scale (VAFS (112)) to assess symptomatic fatigue at that point in time (i.e.,
“acute” fatigue). A ruler was used to score the VAFS, as each number (1 through 10)
was separated by 1 centimeter. For all fatigue measures, a higher score reflects greater
fatigue.

Physical Activity. To characterize and quantify habitual physical activity level,
participants wore an accelerometer (GT1M, Actigraph Inc., Pensacola, FL) around their
waist for 7 days, during all waking hours. An activity log was also provided for
participants to record their daily activities and ensure appropriate wear time.
Acceleration counts were acquired at a sampling frequency of 30 Hz and averaged in
30-s epochs. Non-representative days, indicated by self-report in the activity log or
incomplete data collection, were not included in the analysis. Data from the
accelerometer were downloaded using ActiLife software (Actigraph Inc., Pensacola,
FL) and exported to a Microsoft Excel spreadsheet (Microsoft Corp., Redmond, WA).
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Total daily accelerometer counts were averaged across a minimum of 5 days and used
to represent the participant’s habitual physical activity level (counts·day-1·1000-1) (20;
65).

Physical Function. Physical function was measured to characterize the study
groups. Participants were timed for their rapid completion of 5 consecutive chair rises,
performed without the aid of their arms. Next, participants were asked to rapidly tap
their foot for 10 s, one foot at a time, to assess neuromuscular function. Foot-tapping
was performed twice and the highest count for each foot used for analysis. Mobility
was assessed by having participants walk for 7.62 m (25 ft), first at a brisk and then at a
usual pace. Each walk was performed twice and the fastest times were used for
analysis.
Isometric Strength and Power

Isometric Strength. Participants were seated upright on the Biodex
dynamometer. The upper body and thigh were stabilized with straps around the
shoulder, waist and thigh. The knee joint was aligned with the axis of the dynamometer
arm, and the leg was secured to the arm using a Velcro strap. The knee angle was fixed
at 90° flexion. Although the KE was the primary muscle group of interest, knee flexors
(KF) were also tested for muscle isometric strength. Torque, velocity, and position data
were acquired at 2500 Hz using a customized data acquisition program in MATLAB
software (Math Works Inc., Natick, MA, U.S.A.).
Three maximal voluntary isometric contractions (MVIC, Nm; 3-4 s duration)
were obtained in the KE and KF, with 2 min of rest between contractions. Verbal
encouragement and visual feedback of torque output (diode light box) were provided to
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ensure a maximal effort by the participant. Maximal effort was confirmed when the
highest 2 MVIC trials were within 10% of one another. Additional trials (no more than
6 trials in total) were performed if this criterion was not met. The highest peak torque
was used as the primary outcome measure of muscle isometric strength.

Power. Following the isometric strength measures, the total range of motion
was set at 70°, starting at 90° flexion from full extension. Participants performed
maximal voluntary dynamic contractions at a range of velocities between 30 and 300
°·s-1, at 30 °·s-1 intervals. Participants performed 2 consecutive maximal voluntary
dynamic contractions at each velocity, with 3-4 s rest between contractions. Two min
of rest between each velocity was provided, to minimize muscle fatigue. The highest
power generated at each velocity was recorded. Peak power was used as the primary
outcome measure and the velocity at which peak power occurred was used for
secondary analysis.
Neural Factors

Motor Unit Discharge Rates. Similar to the muscle testing protocol, participants
were seated upright in a custom-built apparatus, with the knee angle fixed at ~90°
flexion. The waist and thighs were secured to the chair by straps to stabilize the body.
A Velcro strap was used to secure the ankle to a cuff that was connected to a force
transducer (Interface SM-250, Scottsdale, AZ, U.S.A.). Participants performed 3
MVICs (4-5 s duration) of the KE, separated by 2 min of rest, to obtain baseline MVIC
prior to insertion of the needle electrode. Verbal encouragement and visual feedback of
torque output was provided on a computer screen using DasyLab Data Acquisition
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software (MicroDAQ.com, Ltd., Contoocook, NH, U.S.A.). If the 2 highest MVIC
trials were not within 10% of one another, additional MVIC trials were performed.
Once peak MVIC was determined, the skin over the patella and belly of the
vastus lateralis muscle was cleansed with alcohol. A stainless steel ground electrode
was taped over the patella. Then, a sterilized, four-wire needle electrode was inserted
into the belly of the vastus lateralis, typically in the lower third of the thigh, to record
intramuscular EMG activity. The electrode consisted of a 27-gauge stainless steel
cannula that housed a square array of four 50 μm-diameter platinum-iridium wires,
which provided 3 recording channels of motor unit activity (52). The ground and
needle EMG electrodes were connected to a Dantec Clinical Electromyograph (Dantec
Counterpoint, Dantec Electronik Medicinsk, Skovlunde, Denmark), where motor unit
activity was displayed on a digital oscilloscope. Analog signals from the EMG
electrode were amplified (200 or 500 μV·division-1) and bandpass filtered (1-10 kHz) in
the Dantec Clinical Electromyograph. Signals from the Dantec and force transducer
were acquired and sampled at 25,600 Hz using DasyLab Data Acquisition software.
Following insertion of the needle electrode, participants performed 3 MVICs (45 s duration), with 2 min of rest between trials. Slight adjustments of the needle
electrode were made between trials to obtain clear recordings of motor unit action
potentials, as well as to sample different motor units. Clear recordings were
characterized as crisp audio feedback and distinct motor unit action potentials displayed
on the Dantec digital oscilloscope. Additional MVICs were performed if there were
fewer than 3 MVICs with clear recordings.
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Individual motor unit identification was performed using a customized spike
recognition algorithm program, which automatically identified motor units based on
discharge history and template-matching (52). Following auto-identification, motor
unit identification was verified manually, and superpositioned and mis-identified motor
units were corrected using a customized motor unit viewing and editing program. The
interpulse interval (ms) between consecutive firings of a given motor unit was
calculated, excluding doublets (≤ 10 ms) and long (≥ 200 ms) intervals. The discharge
rate (pulses per second, pps) of a given motor unit was calculated by taking the inverse
of the interpulse interval. The highest motor unit discharge rate (maxMUDR) was taken
from an average of the 5 fastest interpulse intervals of a given motor unit. To obtain
one value for each participant, all maxMUDR were averaged across motor units. As a
secondary measure, the coefficient of variation of the mean motor unit firings was
calculated for each motor unit to assess motor unit discharge variability. All
coefficients of variation were averaged across motor units to obtain one value for each
participant.

Spasticity. Spasticity was quantified using the passive mode on the Biodex
dynamometer. Similar to the power set-up, the total range of motion was set at 70°,
starting at 90° flexion from full extension. Participants were asked to remain relaxed
while the leg was moved passively by the dynamometer. Torque, velocity and position
were recorded during passive knee extensions were conducted at 10 °·s-1 and from 30 to
300 °·s-1, at 30 °·s-1 increments (Figure 5.1A). Passive torque obtained at 10 °·s-1
consisted of torque due to gravity and visco-elastic properties of the muscle, and was
used to correct passive torque obtained at velocities ≥ 30 °·s-1. Net passive resistive
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torque and velocity were averaged across 20° and 50° extension from the starting
position, for data collected at each velocity setting (Figure 5.1B). Because the
dynamometer was unable to passively achieve velocities > 180 °·s-1, a second-order
polynomial fit was applied to the average passive torque and velocity data for the
prescribed velocities between 30°·s-1 and 300°·s-1 (Figure 5.1C). Thus, for each
participant, the equation obtained from the fit was used to estimate passive torque at all
velocities achieved during the voluntary dynamic contractions (see Power section,
above). Finally, the percentage of KF passive-to-KE voluntary torque was calculated
for each participant, to examine the contribution of KF spasticity on KE voluntary
torque production.

Voluntary Rate of Force Development. The maximal rate of force development
during a maximal voluntary contraction was determined by the first derivative of the
torque trace and expressed as the percentage of peak force per millisecond. To examine
group differences in neural contributors to force production, the voluntary rate of force
development was normalized to the stimulated rate of force development. See
Contractile Function section, below, for more detail.
Muscle Factors

Contractile Function. To assess contractile function, 7.6 x 12.7 cm adhesive
pad electrodes (VQ OrthoCare, Irvine, CA) were placed at the proximal and distal ends
of the KE muscles. A stimulus train (80 Hz, 500 ms) was applied using a constant
current stimulator (model DS7A, Digitimer, Hertfordshire, UK), in an isometric
condition. The stimulation intensity was determined by incrementing the current until
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50% of MVIC was achieved. The maximal rate of force development (RFD; % peak
force·ms-1) was determined from the first derivative of the torque trace.

Muscle Size. Magnetic resonance imaging (MRI) of the thigh was conducted
using a 1.5 Tesla whole-body system (Siemens Medical Solutions USA, Inc., Malvern,
PA) in the MRI Center at Cooley Dickinson Hospital. Participants lay supine on a bed
with 2 phase-array coils placed over the thighs. The bed was automatically moved into
the bore so that the mid-thigh was positioned in the isocenter of the magnet. Forty-six
T1-weighted axial images were acquired in series, using the following parameters: 256
x 256 matrix, field of view of 300 mm, 2 averages, and slice thickness of 6 mm with no
gaps.
All images were processed using a custom-written MATLAB program. Slices
were visually inspected for quality and approximate location of the largest muscle
cross-sectional area (mCSA). The largest slice and the 6 to 10 slices on either side of it
were analyzed. For each slice, signal intensity thresholds were determined to
discriminate contractile from non-contractile tissue (58), and the KE muscle group was
outlined manually. From this analysis, ~7 of the largest, consecutive fat-free slices
were identified, re-analyzed, and averaged across trials. The mean of the 3 largest
mCSAs (cm2) was used as the measure of muscle size.

Specific Strength and Specific Power. Peak isometric torque and power were
normalized to mCSA, to estimate specific strength (Nm.cm-2) and specific power
(W.cm-2), respectively.
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Statistical Analyses
All statistical analyses were performed using Statistical Analysis Software (SAS
Institute Inc., version 8.0, Cary, NC). Normality tests were conducted on all variables
to determine the appropriate statistical tests for group comparisons.
The following tests were performed to address our hypotheses. Analysis of
variance (ANOVA) was used to detect group differences in peak isometric torque, peak
power, mCSA, specific strength, specific power, RFD, maxMUDR, and voluntary RFD
in the KE muscle group. Age, gender and physical activity were used as covariates in
all ANOVA tests, because of their known effects on muscle function. Non-normally
distributed variables (peak isometric torque, maxMUDR, voluntary RFD, stimulated
RFD) were log-transformed and verified for normality prior to performing the ANOVA.
To detect differences in spasticity (KF passive torque) and its effect on KE power
across the range of velocities (percentage of KF passive-to-KE voluntary torque), a 2factor (group, velocity) repeated measures ANOVA was used. If significant
interactions (p≤ 0.05) were observed, Tukey’s post-hoc test was used to determine
where group differences occurred.
Statistical analyses were also performed on the descriptive and secondary
outcome variables. Unpaired t-tests were used to detect group differences in age,
height, mass, BMI, foot-tap speed, and MFIS score. Wilcoxon tests were used to detect
group differences in physical activity, chair rise time, 7.62 m walk time (usual and brisk
pace), FSS and VAFS. Analysis of variance (ANOVA) with covariates of age, gender
and physical activity level was used to detect group differences in velocity at which
peak power was achieved, KF MVIC, peak power, coefficient of variation of mean
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motor unit firings, and stimulated torque. Because the velocity at which peak power
was achieved was not normally distributed, this measure was log-transformed prior to
performing the ANOVA. Two-factor (group, velocity) repeated measures ANOVA was
used to detect group differences in power and specific power across the range of
velocities. If significant interactions (p≤ 0.05) were observed, Tukey’s post-hoc test
was used to determine where group differences occurred.
Linear regressions were performed to examine associations of strength and
power with mechanisms of weakness and physical function. These regressions were
used to clarify the contributions of each mechanism of force production to muscle
weakness in MS, as well as the impact of weakness on physical function. An
interaction term was included in the regression model to test if there were significant
group differences in the associations of strength and power with mCSA and
maxMUDR.
Means ± SD and precise p-values are presented throughout the document,
including figures and tables. Significance level was set at p≤ 0.05.
Results
Group Characteristics
Age, height, mass, BMI, and physical activity level were not different between
groups (Table 5.1). Compared with non-MS controls, the MS group had greater
symptomatic fatigue (MFIS, FSS, VAFS), longer time to complete 5 chair rises, lower
foot-tap speed, and slower walk times (Table 5.1). One individual with MS was unable
to perform the chair rise task without the use of her arms; she also had a 3- to 4-fold
higher time to complete the 7.62 m walk at usual and brisk pace (19.5 s and 18.5 s,
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respectively) relative to the MS group. Therefore, this individual’s values were not
included in the statistical analyses for group differences in chair rise and walk times.
Muscle Weakness in MS
Individuals with MS had lower MVIC torque in the KE (Table 5.2) and KF (46
± 13 Nm and 64 ± 22 Nm, p=0.0007, respectively) muscles, compared with controls.
There was a group effect for KE power across velocities that showed lower power
production in persons with MS compared with controls (p=0.02; Figure 5.2), with no
group-by-velocity interaction (p=0.13). Peak power in the KE was lower in MS than
control (Table 5.2). The velocity at which peak power was achieved was similar across
groups (controls: 272 ± 36 °·s-1, MS: 251 ± 45 °·s-1, p=0.16). Peak torque and power
were both positively associated with chair rise time, timed 7.62 m usual and brisk walk
times, and FSS (Table 5.3; see Appendix C for figures).
Neural Mechanisms

Motor Unit Discharge Rates. When participants were asked to perform an
MVIC with the needle inserted into the muscle for the MUDR recordings, the average
relative torque achieved tended to be lower in control (81 ± 10 % of baseline MVIC)
compared with MS (88 ± 9 % of baseline MVIC, p=0.06). A total of 179 motor units
were identified (97 for control and 82 for MS). Maximal MUDR during the MVIC was
lower in MS (22.7 ± 7.9 pps) compared with control (28.5 ± 8.1 pps, p=0.04; Figure
5.3). The coefficient of variation of mean motor unit firings were not different between
groups (controls: 0.188 ± 0.054, MS: 0.172 ± 0.086, p=0.32). Maximal MUDR was
associated with peak torque and peak power (Figure 5.4). Within the control group,
maxMUDR was not associated with peak torque (r=0.45, p=0.11) and peak power
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(r=0.48, p=0.09). Within the MS group, maxMUDR was associated with peak power
(r=0.57, p=0.03) but not peak torque (r=0.35, p=0.23). There were no significant
differences in the associations (torque-by-maxMUDR interaction, p=0.61; power-bymaxMUDR interaction, p=0.39) between groups.

Spasticity. Knee flexor passive torque across all velocities was not different
between groups (p=0.31; Figure 5.5A), and there was no significant group-by-velocity
interaction (p=0.22). Persons with MS tended to have a higher percentage of KF
passive-to-KE voluntary torque (Figure 5.5B), and there was no group-by-velocity
interaction (p=0.56).
Due to the large amount of variability in spasticity within the MS group,
individuals with MS were separated into 2 sub-groups: those with spasticity (passive
torque ≥ 2 SD above controls; n=5) and a non-spastic group (passive torque <2 SD from
mean for controls; n=9). Those individuals with spasticity had higher KF passive
torque compared with the non-spastic group (p=0.0001; Figure 5.6A), indicating
significant KF spasticity in these individuals. A significant group-by-velocity
interaction (p<0.0001) indicated that these individuals had greater passive torque at
velocities from 180 °·s-1 to 300 °·s-1. Further, the percentage of KF passive-to-KE
voluntary torque was higher in this subset compared to the non-spastic MS sub-group
(p<0.0001; Figure 5.6B). A significant group-by-velocity interaction (p<0.0001)
showed that those with spasticity had a greater percentage of KF passive-to-KE
voluntary torque at velocities of 210 °·s-1 to 300 °·s-1. There were no differences in
isometric torque, power, or any measures of force production between individuals with
and without spasticity in MS (p≥ 0.11; Appendix D). Notably, within the MS group,
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spasticity was modestly associated with physical activity and walk times (r≥ 0.51, p≤
0.08), but not associated with time to complete chair rises (r=0.10, p=0.70; Appendix
E).

Voluntary Rate of Force Development. Neither the maximal voluntary RFD, nor
the voluntary RFD normalized to stimulated RFD, were different between groups
(Table 5.2). These results suggest no slowing of neural activation of the muscle during
an isometric contraction in the MS group compared with controls.
Muscle Mechanisms

Muscle Size. Knee extensor mCSA was lower in MS (n=14) compared with
control (n=11; Table 5.2). Muscle size was associated with peak isometric torque and
peak power (Figure 5.7), for all participants combined. Within each group, muscle size
was associated with peak isometric torque (control: r=0.77, p=0.006; MS: r=0.63,
p=0.02) and peak power (control: r=0.72, p=0.013; MS: r=0.61, p=0.022). There were
no significant differences in the associations (torque*mCSA, p=0.79; power*mCSA,
p=0.995) between groups.

Specific Strength and Specific Power. There were no group differences in
specific strength, but specific power was lower in MS compared with control (Table
5.2). Specific power across velocities was lower in MS (n=14) than control (n=11;
p=0.05; Figure 5.8), with no group-by-velocity interaction (p=0.38). Maximal MUDR
tended to be associated with specific power (r=0.55, p=0.06) for all participants
combined. There was no association within each group between maxMUDR and
specific power (control: r=0.72, p=0.11; MS: r=0.45, p=0.79).
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Contractile Function. The rate of force development in response to a stimulated
contraction was not different between MS and control (Table 5.2), suggesting that rate
of cross-bridge cycling is similar across groups.

Discussion
The aim of this study was to identify the mechanisms of muscle weakness in
persons with MS. As we hypothesized, persons with MS had lower isometric strength,
power, MUDR, specific power, and smaller muscle size compared with controls.
Contrary to our hypotheses, we showed no difference in specific strength, measures of
spasticity, voluntary RFD, and stimulated RFD between persons with MS and controls.
Therefore, the primary mechanisms of weakness in MS were lower MUDR and smaller
muscle size. Differences in peak isometric torques were abolished when torque was
normalized to muscle size, indicating that smaller muscle size explains a large portion
of lower isometric strength. However, differences in peak dynamic power were reduced
when power was normalized to muscle size, but specific power remained lower in
persons with MS compared with controls. These data suggest that neural factors (i.e.,
MUDR), in addition to smaller muscle size, explain a portion of lower dynamic power
in persons with MS. Thus, the mechanisms of weakness in MS may be specific to the
contraction mode.
Muscle weakness in MS
We observed that moderately-impaired persons with MS had lower KE strength
(23%), KF strength (29%) and KE power (32%) compared with controls. Our results
agree with previous studies that have shown 16-57% deficits in isometric (18; 80; 82;
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83; 111; 113) and dynamic (3; 16; 21; 63; 99; 121) torque in persons with MS compared
with controls. Isometric strength and peak power, respectively, appeared to explain on
average ~22% and ~17% of the variance in physical function. These associations
suggest that muscle weakness may partially affect the performance of activities of daily
living. In addition, we observed that isometric strength and power were associated with
FSS, but not MFIS or VAFS. The FSS consists of 9-items that focus on physical
fatigue, whereas the 21-item MFIS focus on physical and mental fatigue and the VAFS
describes global fatigue. Thus, muscle weakness may partially explain physical fatigue
experienced by some of the participants.
Smaller muscles, similar specific strength, and lower specific power in MS
The KE have been shown to be vulnerable to atrophy during disuse in the
elderly (1; 27). Despite no group difference in physical activity (Table 5.1), we showed
that persons with MS had a 17% lower maximal mCSA compared with controls. In this
study, the mCSA values were comparable to those observed by White et al. (127) in the
KE. Muscle size accounted for ~55% of the variance in isometric strength and dynamic
power (Figure 5.7), indicating that smaller muscle size explains a significant portion of
the muscle weakness observed in persons with MS. This relationship has also been
observed in the elderly in the ankle dorsiflexor muscles (56).
Specific strength of the KE was not different between MS and control,
suggesting that muscle quality was similar across groups in the isometric condition.
This result agrees with Kent-Braun et al. (57), who observed no difference between MS
and control in specific strength of the ankle dorsiflexors. To our knowledge, we are the
first to show lower specific power in MS compared with control, suggesting that neural

81

factors, such as lower MUDR, were likely explaining lower peak power production in
MS.
No difference in the RFD during a stimulated contraction across groups
The maximum RFD elicited by electrical stimulation has been used in previous
studies as a measure of the rate of cross-bridge cycling (28; 30; 113). We observed no
difference in the RFD in the KE between persons with and without MS, suggesting that
the rate of cross-bridge cycling was similar across groups. De Haan et al. (28) have
observed no differences in RFD between MS and control, using a current intensity to
elicit 30% MVIC in the KE. The lack of difference in RFD between groups may be
that the current intensity used to elicit submaximal torque was insufficient to recruit all
muscle fibers. However, using a supramaximal stimulus, de Ruiter et al. (30) showed
similar RFD across groups in the adductor pollicis muscle, whereas Sharma et al. (113)
showed lower RFD in the ankle dorsiflexors in MS compared with control. At the
single fiber level, cross-bridge kinetics were not different between persons with MS and
controls (17; 44), supporting our observations. Thus, cross-bridge kinetics are likely
not a mechanism for muscle weakness in persons with MS.
Slower MUDR in persons with MS
We observed that persons with MS had ~20% slower maximal MUDR in the
vastus lateralis muscle compared with controls. Only one other study has examined
MUDR during a MVIC and observed ~ 46% lower maxMUDR in a small group of 4
ambulatory persons with MS compared with 16 controls (106). Notably, motor unit
discharge variability during a maximal voluntary contraction was not different between
groups, suggesting that the pattern of motor unit discharges is similar between MS and
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control. No studies have examined motor unit discharge variability during maximal
contractions in persons with MS compared with control. However, Dorfman et al. (33)
observed increased motor unit discharge variability in MS compared with control
during submaximal contractions in various muscle groups (brachial biceps, brachial
triceps, anterior tibial).
Slower rate-coding may be a consequence of demyelination in MS, generating
prolonged motor conduction (12; 43; 123) and after-hyperpolarization period (10; 12) in
persons with MS. Redistribution of sodium channels in the demyelinated areas of the
axon (25) may explain the slowed recovery of the motor neuron (10; 12). Maximal
MUDR may account for ~31% and 26% of the variance in isometric strength and
power, respectively, indicating the importance of rate-coding on both contraction
modes. In addition, maximal MUDR was shown to explain 25% of the variance in
specific power, suggesting that rate-coding may be one mechanism of specific power.
Spasticity in MS
Spasticity can be a significant problem in persons with MS. Spasticity in an
antagonist muscle is a potential mechanism for power loss in an agonist muscle,
because of the antagonist’s resistance to passive movement due to a hyperexcitable
stretch reflex (64). Antagonist co-activation may slow the velocity of a dynamic
contraction and, thus, decrease the power generated by an agonist muscle. This
phenomenon could explain some of the muscle weakness in MS, particularly during
high-velocity contractions. Using the dynamometer, we showed no difference in KF
passive torque during knee extension between persons with MS and controls. The
percentage of KF passive-to-KE voluntary torque was slightly higher in persons with
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MS compared with controls, although this was not statistically significant. In a subgroup of individuals with spasticity, we observed higher contributions of KF passive
torque to lower KE voluntary torque compared with a non-spastic group during
maximal voluntary dynamic contractions (Figure 5.6). However, a larger sample of
individuals with and without spasticity in MS is needed to elucidate the role of
spasticity on physical activity and physical function.
Contrary to our findings, Nuyens et al. (90) observed a velocity-dependent
increase in KE and KF passive torque production at the muscle’s most stretched
position in persons with MS. The discrepancy between studies may be due to different
populations of MS individuals studied. We recruited mild-to-moderately impaired,
ambulatory individuals with MS; whereas Nuyens et al. (90) studied highly-impaired
persons with MS, most of whom used wheelchairs. Spasticity may reside in muscles
other than the knee flexors, and future studies are needed to clarify the contribution of
antagonist muscle spasticity on agonist power production in other muscle groups.
The measure of spasticity using the dynamometer is not without limitations.
Although settings were made to dictate the velocity of passive movement, target
velocity was not achieved during passive movements at settings >180 °·s-1, due to
constraints in the dynamometer preset by the manufacturer. Because we were interested
in examining the effect of KF spasticity on KE power production, a quadratic equation
was determined for each individual to estimate torque resistance at the same velocities
achieved by each person during maximal voluntary dynamic contractions, to overcome
the limitations of the dynamometer. A major assumption in this approach was that
resistive torque at velocities greater than >180 °·s-1 would increase in a quadratic
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manner. Overcoming this limitation in the acceleration setting would allow a better
understanding of the passive torque-velocity relationship to characterize spasticity.
Voluntary RFD is not different across groups
We observed no difference in either voluntary RFD or normalized RFD between
MS and control (Table 5.2), suggesting that neural activation of force production was
not different across groups during an isometric contraction. This data supports our lack
of difference in specific strength, where group differences in isometric strength were
abolished when torque was normalized to muscle size. High frequency bursts of motor
unit discharges have been observed in young men during voluntary rate of force
development during fast, ballistic contractions (32). Thus, during isometric
contractions, muscle activation pattern may not be different between persons with MS
and controls.
Although Desmedt et al. (32) showed high rate-coding during ballistic isometric
contractions, the results provide some insight to the potential role of rate-coding in
contraction velocity of power production. Because dynamic contractions were ballistic,
rate-coding may have had a substantial role in producing maximal power, particularly
during high-velocity contractions. It may be that rate-coding during force development
may not be different between MS and control and likely explain the lack of difference
in RFD across groups. Unfortunately, we were not able to reliably measure rate-coding
during dynamic contractions, due to noise artifacts and the loss of motor unit potentials,
particularly during rapid movement.
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Future Directions
In this study, we have shown differences in isometric strength, power, specific
power, MUDR and muscle size between persons with and without MS. Previous
research has shown that resistance training can improve all of these variables.
Resistance training has been shown to be effective in increasing strength and power in
persons with MS (31; 48; 118; 127). However, the specific adaptations explaining the
increase in isometric strength and power have not been determined. It is well
recognized that long-term resistance training can increase muscle size. Neural
adaptations have also been shown to occur during short-term resistance training in nonMS adults (52; 69; 95; 122). Studies in older adults have shown increases in maximal
motor unit discharge rates (52) and a reduction in antagonist co-activation (49)
following resistance training. Because the pathophysiology of MS affects the central
nervous system, it is not known whether neural adaptations would be blunted following
short-term resistance training. However, resistance training studies in MS showed
improvements in power without increases in muscle mass (115; 127), suggesting that
neural factors may be contributing to improvements in power production. Additional
studies are needed to determine the mechanistic adaptations to a resistance training
program in persons with MS.
Conclusion
The important mechanisms of muscle weakness in MS appear to be smaller
muscle size and lower MUDR, each of which may contribute differently to weakness
depending on contraction mode. The identification of these mechanisms provides an
evidence-based rationale for the use of a resistance training intervention to increase
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strength and power in persons with MS. The improvement and maintenance of neural
activation and muscle size through resistance training may allow persons with MS to
increase their physical activity, manage symptoms of MS, and improve their quality of
life.
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Figure legends
5.1. Spasticity data for a female with MS. A) Individual torque traces during knee
extension for each velocity, corrected for torque due to inertia. The x-axis
represents the range of motion with 0° being the starting position of 90° flexion.
B) Net torque traces, calculated by subtracting torque from 10 °·s-1 for each
velocity to correct for gravity and visco-elastic properties of the muscle. Torque
was averaged across 20-50° extension, indicated by the bar. C) Torque averaged
across 20-50° extension, for each velocity. The data were fit to a second-order
polynomial and the derived equation was used to estimate torque at the same
velocities achieved during voluntary dynamic contractions.
5.2. MS had lower KE power across velocities compared with control (p=0.02). Data
are mean ± S.D. n=14 in each group.
5.3. Lower maximal MUDR of the vastus lateralis muscle was observed in persons
with MS (22.7 ± 7.9 pps) compared with controls (28.5 ± 8.1 pps, p=0.04) during
maximal voluntary isometric contractions. n=14 in each group. Square symbols
denote group mean with standard deviation bars. Circles and triangles represent
women and men, respectively.
5.4. Maximal MUDR was associated with peak isometric torque (A; r=0.56, p=0.002)
and peak dynamic power (B; r=0.51, p=0.005). n=14 in each group for each
variable. Within the control group, maxMUDR was not associated with peak
torque (r=0.45, p=0.11) and peak power (r=0.48, p=0.09). Within the MS group,
max MUDR was associated with peak power (r=0.57, p=0.03) but not peak torque
(r=0.35, p=0.23).
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5.5. There was no difference in KF passive torque (A) between MS and control
(p=0.31). MS tended to have a higher percentage of KF passive-to-KE voluntary
torque (B) compared with controls (p=0.067). Data are mean ± S.D. n=14 in each
group.
5.6. Participants with MS were separated into 2 sub-groups: those with spasticity
(passive torque ≥2 SD above control; n=5) and a non-spastic group (passive
torque <2 SD from mean for controls; n=9). Individuals with spasticity had higher
KF passive torque compared with the non-spastic sub-group (p=0.0001; A).
Further, the percentage of KF passive-to-KE voluntary torque was higher in
persons with spasticity than non-spastic sub-group (p<0.0001; B). * indicates a
significant group x velocity interaction (p<0.0001).
5.7. Knee extensor muscle size is associated with peak isometric torque (A; r=0.75,
p<0.001) and peak power (B; r=0.74, p<0.0001). Within each group, muscle size
was associated with peak isometric torque (control: r=0.77, p=0.006; MS: r=0.63,
p=0.02) and peak power (control: r=0.72, p=0.013; MS: r=0.61, p=0.022). n=14
in each group for isometric torque and power. For mCSA, n=11 for control and
n=14 for MS.
5.8. MS (n=14) had lower specific power across velocities compared with control
(n=11; p=0.05). Data are mean ± S.D.
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Table 5.1. Group Characteristics
Data are presented as means ± S.D. C.I., 95% confidence interval for the difference in
means across groups; BMI, body mass index; MFIS, Modified Fatigue Impact Scale;
FSS, Fatigue Severity Scale; VAFS, Visual Analog Fatigue Scale. --, no C.I. because
variables were non-normally distributed. All variables have n=14 in each group, except
for chair rise and 7.62 m walk times (n=14 controls, 13 MS).
Variable

Control

MS

C.I.

p value

Age (years)

46 ± 7

48 ± 9

-8.5, 4.2

0.49

Height (m)

1.68 ± 0.10

1.66 ± 0.08

-0.05, 0.09

0.53

Mass (kg)

73.4 ± 16.3

74.7 ± 13.6

-13.0, 10.4

0.82

BMI (kg·m-2)

25.7 ± 4.4

26.9 ± 4.1

-4.5, 2.0

0.44

Physical Activity
(counts·day-1·1000-1)

259 ± 146

193 ± 92

--

0.26

MFIS

15 ± 15

37 ± 14

-32.7, -10.0

0.0006

FSS

2.3 ± 1.1

4.5 ± 1.8

--

0.002

VAFS

1.5 ± 0.7

2.7 ± 1.9

--

0.02

Chair rise time (s)

8.26 ± 2.09

12.93 ± 4.13 --

0.001

left 47 ± 10

35 ± 7

5.3, 18.7

0.001

50 ± 10

36 ± 8

7.1, 21.5

0.004

usual 5.08 ± 0.60

6.02 ± 0.91

--

0.01

brisk 3.86 ± 0.45

4.47 ± 0.83

--

0.06

Foot-tap speed
(counts in 10 s)

right
7.62 m walk time (s)
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Table 5.2. Knee Extensor Muscle Characteristics
Data are presented as means ± S.D. mCSA, fat-free muscle cross-sectional area; RFD,
maximal rate of force development. Voluntary RFD was normalized to stimulated RFD
and expressed as a percentage. All variables have n=14 in each group, except mCSA,
peak specific strength and peak specific power (n=11 controls, 14 MS).
Variable

Control

MS

p value

Peak Isometric Torque (Nm)

140 ± 51

108 ± 29

0.03

Peak Power (W)

320 ± 136

216 ± 73

0.002

mCSA (cm2)

52.9 ± 14.8

43.9 ± 7.8

0.04

Specific Strength (Nm·cm-2)

2.63 ± 0.67

2.46 ± 0.49

0.48

Specific Power (W·cm-2)

6.09 ± 1.69

4.92 ± 1.28

0.05

Stimulated RFD (% peak force·ms-1)

1.24 ± 0.29

1.15 ± 0.39

0.37

Voluntary RFD (% peak force·ms-1)

0.66 ± 0.29

0.64 ± 0.20

0.81

53 ± 17

58 ± 21

0.44

Voluntary-to-simulated RFD*100 (%)
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Table 5.3. Associations between KE strength, peak power, physical function and
symptomatic fatigue
FSS, Fatigue Severity Scale; MFIS, Modified Fatigue Impact Scale; VAFS, Visual
Analog Fatigue Scale.
KE strength (Nm)
Variable

KE peak power (W)

r

p-value

r

p-value

0.42

0.03

0.44

0.02

usual

0.46

0.02

0.39

0.04

brisk

0.53

0.005

0.42

0.03

FSS

1.00

<0.0001

0.44

0.02

MFIS

0.32

0.10

0.28

0.14

VAFS

0.26

0.19

0.17

0.40

Chair rise time (s)
7.62 m walk time (s)
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Figure 5.1. Spasticity data for a female with MS
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Figure 5.2.
MS had lower KE power across velocities compared with control (p=0.02). Data are
mean ± S.D. n=14 in each group.
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Figure 5.3.
Lower maximal MUDR of the vastus lateralis muscle was observed in persons with MS
(22.7 ± 7.9 pps) compared with controls (28.5 ± 8.1 pps, p=0.04) during maximal
voluntary isometric contractions. n=14 in each group. Square symbols denote group
mean with standard deviation bars. Circles and triangles represent women and men,
respectively.
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Figure 5.4.
Maximal MUDR was associated with peak isometric torque (A; r=0.56, p=0.002) and
peak dynamic power (B; r=0.51, p=0.005). Within the control group, maxMUDR was
not associated with peak torque (r=0.45, p=0.11) and peak power (r=0.48, p=0.09).
Within the MS group, max MUDR was associated with peak power (r=0.57, p=0.03)
but not peak torque (r=0.35, p=0.23). n=14 in each group for each variable.
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Figure 5.5.
There was no difference in KF passive torque (A) between MS and control (p=0.31).
MS tended to have a higher percentage of KF passive-to-KE voluntary torque (B)
compared with controls (p=0.067). Data are mean ± S.D. n=14 in each group.
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Figure 5.6.
Participants with MS were separated into 2 sub-groups: those with spasticity (passive
torque ≥2 SD above control; n=5) and a non-spastic group (passive torque <2 SD from
mean for controls; n=9). Individuals with spasticity had higher KF passive torque
compared with the non-spastic sub-group (p=0.0001; A). Further, the percentage of KF
passive-to-KE voluntary torque was higher in persons with spasticity than non-spastic
sub-group (p<0.0001; B). * indicates a significant group x velocity interaction
(p<0.0001).
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Figure 5.7.
Knee extensor muscle size is associated with peak isometric torque (A; r=0.75,
p<0.001) and peak power (B; r=0.74, p<0.0001). Within each group, muscle size was
associated with peak isometric torque (control: r=0.77, p=0.006; MS: r=0.63, p=0.02)
and peak power (control: r=0.72, p=0.013; MS: r=0.61, p=0.022). n=14 in each group
for isometric torque and power. For mCSA, n=11 for control and n=14 for MS.
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Figure 5.8.
MS (n=14) had lower specific power across velocities compared with control (n=11;
p=0.05). Data are mean ± S.D.
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CHAPTER 6
PRÉCIS OF DISSERTATION
Novelty
This dissertation study was the first to systematically address neural and
muscular mechanisms of muscle weakness in persons with MS compared with agematched controls. The results of this dissertation suggest that lower motor unit
discharge rates and smaller muscle size are primary mechanisms of knee extensor
weakness in MS. Differences in isometric strength across groups were abolished when
torque was normalized to muscle size. Differences in dynamic power were lessened
when muscle size was accounted for, but specific power remained lower in persons with
MS compared with controls, suggesting that neural factors explains some of the lower
power production in persons with MS. These results suggest that mechanisms of
weakness in MS may be contraction-mode specific.
This dissertation study was also the first to examine the role of spasticity in the
KF on dynamic power production in the KE. Spasticity in an antagonist muscle may
impede the velocity component of power production in an agonist muscle. In persons
with MS, 5 individuals with spasticity in the knee flexor muscles had higher KF passive
torque, and the percentage of KF passive-to-KE voluntary torque was large during highvelocity contractions compared with a non-spastic subgroup. These results suggest that
spasticity in an antagonist muscle may act to co-activate during agonist power
production, and thereby, contribute to some of the weakness in persons with MS.
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Significance and Impact
The significance of this dissertation study is identification of key mechanisms
(lower motor unit discharge rates and smaller muscle size) of muscle weakness within
the same sample population with MS compared with age-matched controls. The
contribution of lower motor unit discharge rates and smaller muscle size has been
shown to be contraction-mode dependent. While lower isometric strength was largely
explained by smaller muscle size, lower dynamic power was attributed to changes in
neural function, in addition to smaller muscle size. Muscle size and motor unit
discharge rates have been shown to improve with a resistance training program in nonMS adults. Thus, this dissertation provides evidence-based knowledge for resistance
training intervention to ameliorate weakness by specifically addressing muscle size and
motor unit discharge rates in MS.
Future Directions
Study 1 of this dissertation has provided key mechanisms of weakness in person
with MS: muscle atrophy and altered neural function. These results provide the
foundation for the proposed Study 2 of this dissertation, examining the effect of 2
weeks of high-intensity resistance training (3 times per week) on muscle strength,
power, motor unit discharge rates, and antagonist muscle co-activation in persons with
and without MS. In general, short-term resistance training is known to improve neural
factors of force production (69), such as increasing motor unit discharge rates (52) and
reducing antagonist co-activation (49). Eight- to 10-week resistance training programs
in persons with MS have demonstrated increases in strength and power (31; 115; 118;
127) without any increases in muscle size (115; 127), suggesting that neural adaptation
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was largely accounting for strength and power improvements. However, no studies
have specifically measured neural adaptation in persons with MS. Thus, Study 2 will
elucidate whether neural adaptations (e.g., motor unit discharge rates) occur following
short-term resistance training in persons with MS and whether the magnitude of neural
adaptation is similar or blunted in persons with MS compared with controls.
Therapeutic interventions may need to target the weaker limb more so than both
limbs together. Anecdotally, persons with MS have indicated that one limb presents
more symptomatic problems than the other. Power asymmetry in the KE muscles has
been observed in persons with MS (21). Because Study 1 examined only the weaker
leg, it may be that therapeutic interventions will need to focus more on the weaker leg
rather than both legs to minimize limb asymmetries, which have been associated with
postural imbalances, lower physical function and symptomatic fatigue (21). Thus, it
would be interesting to examine whether resistance training in the weaker limb
minimizes power asymmetry and how the mechanisms of this improvement might
affect the trained and untrained limbs in persons with MS.
Further research into the role of spasticity on power production in MS is needed.
Spasticity has a tremendous impact on physical function and overall quality of life.
Although we did not show spasticity in the KF in 9 of the 14 participants with MS,
spasticity may reside in other muscle groups (e.g., knee extensors, plantarflexors) and
may affect the opposing muscle’s ability to generate maximal power production.
Quantifying spasticity in other muscles, and its impact on power production in opposing
muscles, is warranted. In addition, the effects of resistance training on spasticity have
not yet been explored in MS. A reduction of spasticity following an acute bout of
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unloaded leg cycling has been observed in persons with MS (73; 74). Therefore, a
combination of resistance training and cycling may be a more effective approach in
mitigating symptoms of MS that affect force production.
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Abstract
A higher energy cost of walking (Cw) is sometimes observed in persons with multiple
sclerosis (MS), and could contribute to their greater symptomatic fatigue. Objective:
To compare Cw at 3 walking speeds in MS and controls, and to examine the
interactions between Cw, symptomatic fatigue and perceived exertion. Design: Nonrandomized controlled study. Setting: Muscle Physiology and Energy Metabolism
Laboratories. Participants: Ten persons with MS and 14 age-matched controls. Main

Outcome Measures: Oxygen consumption (VO2) was obtained by open-circuit
spirometry and indirect calorimetry at rest and during treadmill walking at 0.6 m·s-1 and
1.4 m·s-1, and at a self-selected, preferred speed. Cw was calculated as net VO2
(walking minus rest; ml·kg-1·m-1). Fatigue and perceived exertion were obtained using
a visual analog fatigue scale and modified Borg scale, respectively. Results: Preferred
speed was not different between groups. Cw was higher in MS compared with controls
across all walking speeds (p=0.003), with a group-by-speed interaction indicating
higher Cw in MS during 0.6 m·s-1 (p=0.001), but not 1.4 m·s-1 or preferred speeds,
compared with controls. MS had greater fatigue and perceived exertion (p≤ 0.004) at
all speeds compared with controls. Cw was associated with perceived exertion during
slow and preferred speeds (r≥ 0.41, p≤ 0.05), but was not associated with fatigue (r≤
0.35, p≥ 0.10). Conclusions: Despite similar preferred speeds, and Cw at preferred and
fast speeds, this MS group exhibited higher fatigue and exertion at all walk speeds.
However, only slow walking induced sufficient challenges to postural control to elicit
higher energy costs in MS. These results suggest that increased postural demands on
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individuals with MS at slower walking speeds may require increased muscular
contributions to maintain balance.
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Introduction
Multiple sclerosis (MS) is an auto-immune disease that is defined by
demyelination of nerves in the central nervous system. Symptoms of MS include
symptomatic fatigue, increased perceived exertion, balance problems, and difficulty in
walking. These symptoms may have a major effect on the ability to perform activities
of daily living and alter physical activity behaviors in persons with MS.
Gait abnormalities, such as slower gait speed (7; 21; 67; 70; 111; 120; 121),
shorter stride length (7; 67; 121), lower cadence (7; 121), and prolonged double-support
phase (7; 67) are often observed in persons with MS. Altered gait characteristics and a
lower preferred walking speed may be functional strategies adopted by individuals with
MS to minimize the risk of falling (21; 104), given that individuals with MS
demonstrate compromised balance. However, these strategies may, in turn, increase the
energy cost of walking (Cw), defined as the net rate of oxygen consumption (VO2;
walking minus resting) per body mass and distance traveled (ml O2·kg-1·m-1).
The metabolic rate while walking primarily reflects the energy costs associated
with muscle activation for maintenance of balance, coordination and posture while
propelling the body forward. In healthy adults, the relationship between Cw and
walking speed has been characterized as a U-shaped curve by Ralston (101); with the
lowest VO2 typically occurring at a preferred walking speed and higher VO2 at lower
and higher speeds, reflecting increased Cw. Individuals with MS have shown higher
Cw, compared with controls, over a range of slow and fast treadmill walking speeds
(91; 93), but not at preferred walking speed. This systematic alteration of Cw across a
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range of speeds in individuals with MS may suggest their use of different postural
control strategies compared with controls.
Fatigue, defined as an overwhelming sense of tiredness, is a highly problematic
symptom of MS (61). It is reasonable to suppose that higher Cw may increase feelings
of fatigue. This could occur both directly, as a result of higher energy expenditure, or
indirectly as a result of elevated body core temperature (61; 126). Heat generated from
higher amounts of muscular activity (i.e., reflecting higher Cw) may exacerbate
symptomatic fatigue in persons with MS. In turn, a worsening of fatigue during
walking, regardless of the cause, could contribute to higher levels of perceived exertion
(or perceptual effort) in persons with MS compared with controls, an effect that could
act to limit physical activity behavior in persons with MS.
Therefore, the aim of this study was to quantify the Cw associated with
prescribed (slow and fast) and preferred walking speeds in persons with MS compared
with age-matched controls, and to explore the relationships between Cw, fatigue,
perceived exertion and physical activity in MS. We hypothesized that persons with MS
would have higher Cw across all speeds compared with controls. We also hypothesized
that symptomatic fatigue and ratings of perceived exertion (RPE) would be lower at
preferred speed compared to the slow and fast speeds, due to lower Cw at this speed.
Finally, we examined whether Cw was associated with symptomatic fatigue, perceived
exertion or habitual physical activity level in our study groups.

110

Methods

Participants
Ten persons with MS (9 females, 1 male) and 14 age-matched individuals
without MS (11 females, 3 males) gave signed informed consent, as approved by the
Institutional Review Board at the University of Massachusetts, Amherst, and in
compliance with the Declaration of Helsinki. Of the 10 individuals with MS, 9 had
relapsing-remitting and 1 had primary progressive subtypes. Participants were recruited
from the university and surrounding communities, as well as through the New England
Chapter of the National MS Society.
Participants were excluded from the study if they had metabolic, non-MS
neurological, cardiovascular or other major diseases; cognitive impairment or mental
disorder that prevented them from following instructions; orthopedic injury or
significant arthritis in the legs; or were unable to walk at a speed of 0.6 m·s-1.
Participants with MS were ambulatory: 7 walked unaided, and 3 needed a cane or
Canadian crutch. No participant with MS had an exacerbation within 6 months prior to
their involvement in the study. Disease duration was 12 ± 8 years (mean ± SD; range 4
to 27 years). Medications taken by the participants with MS included [# of
participants]: immunomodulators [9], anti-depressants [4], anti-convulsants [3], antianxiety [3], anti-spasticity [2], medications for bladder control [2] and for wakefulness
[2]. Five of the 14 controls were taking the following medications [# of participants]:
birth control [2], levothyroxine [2] and prilosec [1].
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Study Design
After an overnight fast (~9 hours), participants reported to the Muscle
Physiology Laboratory between 7:00 and 10:00am, where they completed the informed
consent process, self-reported Expanded Disability Status Scale (sEDSS (14)), medical
history form, and Physical Activity Readiness Questionnaire (119). Height (m) and
body mass (kg) were determined, and body mass index (BMI; kg·m-2) was calculated.
Participants completed the Fatigue Severity Scale (FSS (60)) and Modified Fatigue
Impact Scale (MFIS; 21-items from Fatigue Impact Scale (38)) to characterize
participant’s fatigue status in the prior 2 and 4 weeks, respectively. Participants were
asked to walk 7.62 m over ground at a brisk pace and then at a preferred pace. Each
pace was performed twice, and the fastest time (s) for each pace was reported.
Following these tests, measures of resting metabolic rate and Cw were collected in
climate-controlled laboratories. Prior to leaving, participants were given an
accelerometer (GT1M, Actigraph Inc., Pensacola, FL) to wear for 7 days to monitor
habitual physical activity.

Energy cost of walking
Metabolic rate was measured at rest while the participant lay supine on a bed,
and during the 3 treadmill walking speeds. Gas exchange measurements were obtained
continuously throughout each test by open-circuit spirometry and indirect calorimetry
(TrueMax2400 Metabolic Measurement System, Parvomedics, Salt Lake City, UT).
Pneumotachometer (to measure volume) and standard gas (16.01% O2 and 3.98% CO2)
calibrations were performed prior to each testing session. As participants breathed
using a one-way valve mouthpiece, expired air was collected and delivered to the
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mixing chamber via a hose. A caliper was placed over the nose to ensure that breathing
was through the mouth only. Participants were instructed to lay supine quietly on a bed
for ~15 minutes to reach and maintain steady-state, defined as the balance between
energy required by working muscles and the rate of ATP production (via oxidative
metabolism). Then, metabolic measures were made for 6-8 min. Resting metabolic rate
(VO2rest) was recorded as the average rate during the final 2 minutes of this period.
Following measurement of VO2rest, participants walked for ~5 min on a treadmill
at each of the 3 speeds, in the following order: 0.6 m·s-1, 1.4 m·s-1, and at a selfselected, preferred speed. Walking speed was ordered in this way to 1) make certain
that participants with MS were able to perform the slow walking speed (particularly
with those who used walking aids), and 2) familiarize each person with the fast walking
speed prior to determining their preferred walking speed. Preferred walking speed was
determined in an oscillatory-decaying manner. Using ~10-s epochs, the investigator set
fast and slow speeds, alternately, decreasing the range with each repetition until the
participant indicated their usual walking speed. Verbal encouragement was provided to
all participants during each walking speed. All participants with MS lightly touched the
handrails for extra sensory support. A second investigator was positioned behind the
treadmill to provide tactile feedback on the back if the participant was walking to close
to the end of the treadmill. Seated rest periods of 5 to 10 min and cold drinks of water
were provided between walking speeds.
For each speed trial, oxygen consumption (VO2walk; ml·kg-1·min-1) was averaged
over the final 2 minutes when steady-state was maintained, and the net VO2 (walking
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minus resting) was used to calculate Cw (ml O2·kg-1·m-1) during slow (Cwslow), fast
(Cwfast), and preferred (Cwpref) walking speeds (Equation 1).
Cw =

VO2 walk − VO2 rest
v

Equation 1

where v is treadmill speed (93).

Symptomatic Fatigue and Rating of Perceived Exertion (RPE)
Symptomatic fatigue and RPE were measured while standing quietly on the
treadmill prior to the first walking trial and again immediately following each treadmill
trial. Acute symptomatic fatigue was measured using the visual analog fatigue scale
(VAFS) (112; 129). Participants were asked to draw a vertical line across a scale
marked 1 through 10, with each number separated by 1 cm. A ruler was used to
measure and score each VAFS, with a smaller score indicating less fatigue. The
modified Borg scale was used to obtain RPE (13; 71; 129). For the post-walk measures,
participants were asked to indicate the VAFS and RPE based on how they felt during
the last 30 s of walking.

Physical Activity
Participants were given an accelerometer (Actigraph Inc., Pensacola, FL) to
wear around the waist for 7 days during waking hours, to monitor habitual physical
activity. An activity log was also provided for participants to record their daily
activities. A minimum of 5 days were included in the analysis of physical activity.
Days that were not typical of habitual physical activity, indicated by self-report on the
activity log, were excluded. Data from the accelerometer were downloaded using
Actigraph’s ActiLife software and exported to a Microsoft Excel spreadsheet. Total
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daily accelerometer counts were averaged across days and divided by 1000 for ease of
reporting (counts·day-1·1000-1) (81).

Statistical Analyses
All statistical analyses were performed using Statistical Analysis Software (SAS
Institute Inc., version 8.0, Cary, NC). Normality tests were conducted on all variables
prior to proceeding with the statistical analyses, to determine the appropriate use of
parametric and non-parametric tests.
Unpaired t-tests were used to examine group differences in age, height, body
mass, BMI, FSS, MFIS, 7.62 m walk time, preferred speed, and VO2rest. Wilcoxon tests
were used to examine group differences in physical activity and baseline VAFS. Twofactor (group, speed) repeated measures analysis of variance was used to detect
differences between groups in Cw, RPE and VAFS across all walking speeds. Linear
regression was used to examine associations between Cw and physical activity, as well
as between Cw, fatigue and RPE at each walking speed. Data are presented as means ±
SD, and precise p-values and 95% confidence intervals are reported where appropriate.

Results

Participants
Age, height, body mass, BMI, and physical activity were similar across groups
(Table 1). Participants with MS scored 4.6 ± 1.1 (range 3 to 6, out of a possible 10) in
the sEDSS. The MS group reported a significantly higher fatigue state (FSS) in the
preceding 2 weeks compared with the control group, and a greater impact of fatigue on
their lives (MFIS; Table 1). Participants with MS had slower 7.62 m walk times at both
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brisk and preferred pace compared with controls (Table 1). Two individuals with MS
(1 female, 1 male) were unable to perform the fast treadmill walking speed and were
statistically treated as missing data points.

Energy Cost of Walking
The groups had similar VO2rest (MS: 2.82 ± 0.65 ml·kg-1·min-1, control: 2.71 ±
0.85 ml·kg-1·min-1, p=0.72) and preferred walking speed (MS: 0.97 ± 0.28 m·s-1,
control: 1.05 ± 0.17 m·s-1, p=0.42). Overall, individuals with MS had higher Cw
compared with controls across walking speeds (Figure 1; p=0.003). A significant
group-by-velocity interaction (p=0.03) showed that persons with MS had significantly
higher Cw compared with controls during the slow, but not fast or preferred, walking
speed (p=0.001).

Symptomatic Fatigue and RPE
At baseline, the acute fatigue state was not different between groups (VAFS: 1.6
± 1.0 in MS, 1.2 ± 0.4 in controls, p=0.72). Overall, fatigue (Figure 2; p=0.001) and
RPE (Figure 3; p=0.004) were higher in persons with MS compared with controls for all
walking speeds. There were no significant group-by-velocity interactions for fatigue
(p=0.07) or RPE (p=0.11). Notably, RPE was significantly associated with Cwpref
(r=0.57, p=0.006) and Cwslow (r=0.41, p=0.05) but not Cwfast (r=0.26, p=0.22; Figure 4).
There were no associations between VAFS and Cw at any speed (r≤ 0.35, p≥ 0.10;
Figure 5).

Physical Activity
Total daily physical activity counts were similar in MS and controls (Table 1).
Physical activity was negatively associated with Cwslow (r=-0.44, p=0.03) and Cwfast
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(r=-0.55, p=0.008), but not Cwpref (r=-0.14, p=0.49; Figure 6). Symptomatic fatigue
was negatively associated with physical activity at all speeds (r≥ -0.49, p≤ 0.02).
Ratings of perceived exertion were negatively associated with physical activity at slow
(r=-0.52, p=0.01) and fast (r=-0.59, p=0.004), but not preferred (r=0.0, p=1.0), walking
speeds.

Discussion
We examined the energy cost of walking in persons with MS compared with
age-matched controls. In contrast to previous reports (93), we observed that Cw was
higher at slow, but not preferred and fast, speed in persons with MS compared with
controls. This result indicates that persons with MS may adopt different strategies
while walking at slow versus faster speeds to maintain postural control. We also
showed that symptomatic fatigue and perceived exertion were higher in persons with
MS compared with controls, but only perceived exertion was associated with Cw.
These results suggest that, in contrast to perceived exertion, symptomatic fatigue may
not develop as a consequence of higher energy costs.

Differential effects of speed on cost of walking in individuals with MS
Resting metabolic rate (VO2rest) was similar across groups, which has been
shown previously (92; 93; 117). We showed that Cw was higher during slow, but not
fast or preferred, walking in persons with MS compared with age-matched controls.
The lack of group differences in Cw during preferred and fast walking indicates a
similar strategy in maintaining posture between groups. Olgiati et al. (93) showed
higher Cw in persons with MS compared with controls during treadmill walking at 2, 3,
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4, and 5 km·h-1 (0.6, 0.8, 1.1, and 1.4 m·s-1, respectively), regardless of speed. In
absolute terms, Cw in our MS group was lower than that reported by Olgiati et al. (93)
(approximate range from slow to fast speeds: 0.33 to 0.22 ml·kg-1·m-1), which may be
attributed to their sample population having greater mobility impairment (50% needed
to use a walking aid) and, consequently, a greater need to activate more muscle to
accomplish the task. Greater mobility impairment has been associated with higher Cw
(72). Tantucci et al. (117) observed no difference in VO2 during an incremental
exercise test using the cycle ergometer between controls and mildly-impaired persons
with MS (EDSS 0.75 ± 0.30 SD). The lack of difference in VO2 may be explained by a
lower postural challenge in persons with MS when using the cycle ergometer versus the
treadmill.
In our MS group, Cw was highest at slow walking and lowest at preferred
walking speeds (Figure 1). This pattern of Cw has been observed in spastic paresis
(131) (MS, spinal cord injury, hemiparesis) and post-stroke (103) patients, suggesting
that there may be greater muscular demand to maintain postural control during slow,
rather than fast, walking in these neurological disease patients. Studies have shown that
postural control in MS during quiet stance is compromised (21; 47). Altered functional
strategies (minimal displacement of center of mass and smaller posterior shift in the
center of pressure) have been observed during gait initiation in women with MS
compared with controls (104), possibly to adjust for postural imbalances (21). To date,
no studies have measured Cw and gait characteristics, concurrently, at different walking
speeds in persons with MS compared with controls.
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Although preferred treadmill speed was similar across groups, there was a large
range of preferred treadmill speeds in both groups, which may be due to having to
identify the preferred speed on the treadmill. Persons with MS (1.31 ± 0.21 m·s-1) had
lower usual 7.62 m walk speed over ground compared with controls (1.52 ± 0.19 m·s-1).
Notably, the preferred treadmill speed was lower than the usual 7.62 m walk speed
(p<0.001) in both groups.

Symptomatic Fatigue and Perceived Exertion are impacted differently during walking
in individuals with MS
Fatigue is a common, disabling symptom of MS (40). As expected, general
fatigue state (FSS) and the impact of fatigue on quality of life (MFIS) were higher in
individuals with MS compared with controls. Prior to the walking tests, acute fatigue
(VAFS) did not differ between the MS and control groups. However, at the end of each
walking trial, both fatigue and perceived exertion were higher in persons with MS
compared with controls (Figures 2 and 3). However, acute fatigue was not associated
with Cw, whereas perceived exertion was, suggesting that there may be other
determinants (i.e., cognitive demands) affecting symptomatic fatigue than increased
energy costs.
In contrast to our results, Morrison et al. (71) showed similar changes in
perceived exertion and heart rate during a graded exercise test on a cycle ergometer
between persons with MS and controls. The differences in perceived exertion observed
between studies may be due to differences in the severity of MS and testing protocol.
Morrison et al.’s MS group had a median EDSS score of 2.75 (71) compared with our
median of 4.5 on the self-reported EDSS instrument. The difference in testing protocol
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(whole-body walking versus cycling) may also have contributed to differences in
outcome. Walking may demand more muscular activity to maintain upright posture
than cycling in persons with MS compared with controls. In addition, we prescribed
absolute speeds, whereas Morrison et al. (71) had participants perform at relative
workloads (% peak VO2), which may explain similar perceived exertion in persons with
MS and controls. We observed that RPE was related to Cw, indicating that higher
perceived exertion may be explained by higher Cw.
Unexpectedly (although there was no VAFS-by-speed or RPE-by-speed
interaction), fatigue and RPE were lowest during slow walking, where Cw was at its
highest; and highest during preferred and fast walking, where Cw was at its lowest. It is
possible that fatigue and exertion worsened over time, given that the speeds were tested
in order from slow to fast to preferred speeds. However, if this were the case, we would
expect an incremental increase in fatigue and exertion following each walking bout.
Instead we observed that fatigue and perceived exertion were not different between fast
and preferred walking speeds. Because the preferred walking speed followed fast
walking, it may be that the non-incremental increase in walking speed may have
prevented any further exacerbation of fatigue and perceived exertion.

Altered Cost of Walking by individuals with MS is not related to Physical Activity
In this study, our groups had similar habitual physical activity based on total
daily accelerometer counts. Using the same methodology, Ng and Kent-Braun (81)
have shown lower physical activity in persons with MS (median EDSS score of 3.0)
compared with controls. This discrepancy may be because we tried to control physical
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activity level by recruiting individuals who were sedentary-to-recreationally active for
both groups.
We observed that lower physical activity was related to higher Cw, suggesting
that de-conditioning, rather than the symptoms of MS, may explain increased energy
expenditure, given that we did not demonstrate group-specific differences in physical
activity. Persons with lower physical activity may be weaker and have less muscular
coordination, which may require more muscular activity to accomplish a given task.
Benedetti et al. (6) observed a decline in Cw at 4 and 6 km·h-1 (1.1 and 1.7 m·s-1)
following a 4-week treadmill walking intervention in 3 MS patients. In contrast, Olgiati
et al. (92) observed no change in Cw in persons with MS, despite improvements in
walking performance, following a 24-week physical therapy rehabilitation program.
The discrepancy between these results may be the difference in the type of interventions
(ramped treadmill walking exercise (6) versus general rehabilitation program (92)).
Thus, increasing physical activity alone may not improve Cw in MS, but may depend
on the type and intensity of the intervention.

Limitations
The walking protocol was conducted on a treadmill because walking over
ground at prescribed speeds is difficult to control. In healthy adults, usual gait patterns
that are normally observed while walking over ground may be altered (2) compared
with walking on the treadmill at preferred speeds. Despite potential gait characteristic
differences between treadmill and over ground walking, elevated Cw is likely attributed
to postural control challenges in MS.
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Another limitation to our walking protocol was that walking was conducted on
the flat surface of a treadmill, whereas most walking environments are uneven. Thus, it
is not possible in this study to determine whether Cw would be altered in MS compared
with controls in a more ecological environment. However, the presence of sensory
deficits in persons with MS could exacerbate this difference in Cw, as uneven surfaces
could present an additional challenge to postural control during gait in these individuals.

Conclusion
Differences in Cw in persons with MS, compared with age-matched controls,
are higher at slow speeds but appear to be abolished at faster speeds. Thus, slow
walking may induce postural control challenges that require greater muscular work.
Unlike perceived exertion, symptomatic fatigue appears to be dissociated from the
energy costs of walking in MS. Symptomatic fatigue and perceived exertion may have
an impact on habitual physical activity behavior, although this does not seem to be
related specifically to the presence of MS.
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Table 1. Group Characteristics
Data are presented as means ± S.D. BMI, body mass index; CI, 95% confidence
interval for the difference in means across groups. FSS, fatigue severity scale. MFIS,
modified fatigue impact scale. 7.62 m walk time is for over ground walking. CI for
physical activity is not provided due to the use of non-parametric analysis to test for
group differences.
Control

MS

CI

p-value

(11F, 3M)

(9F, 1M)

Age (years)

46 ± 7

45 ± 8

-5.2, 7.7

0.70

Height (m)

1.68 ± 0.10

1.66 ± 0.06

-0.1, 0.1

0.47

Body Mass (kg)

73.4 ± 16.3

74.4 ± 14.0

-14.3, 12.2

0.87

BMI (m·kg-2)

25.7 ± 4.4

27.0 ± 4.5

-5.1, 2.5

0.50

FSS

2.3 ± 1.1

4.3 ± 1.8

-3.2, -0.8

0.008

MFIS

15 ± 15

40 ± 15

-37.1, -11.9

0.0007

7.62 m walk time (s) brisk

3.9 ± 0.5

4.7 ± 0.8

-1.3, -0.2

0.02

preferred

5.1 ± 0.6

6.0 ± 1.0

-1.6, -0.3

0.02

259 ± 146

209 ± 89

--

0.63

Variable

Physical Activity
(counts·day-1·1000-1)
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LIST OF FIGURES
Figure 1. Energy cost of walking at 3 speeds. The cost of walking (Cw) was
higher in persons with MS compared with controls, at all speeds (p=0.003). * indicates
a significant group-by-speed interaction, where Cw at 0.6 m·s-1 was higher in MS
compared to controls (p=0.001). Data are presented as means ± S.D. Note that the
order of trials was: slow, fast, preferred.
Figure 2. Acute symptomatic fatigue at 3 walking speeds. Visual analog
fatigue scale (VAFS) score was higher in persons with MS than controls for all walking
speeds (p=0.001). A VAFS score of 1 indicated “no fatigue” and 10 indicated “severe
fatigue”. Data are presented as means ± S.D. Note that the order of trials was: slow,
fast, preferred.
Figure 3. Ratings of perceived exertion at 3 walking speeds. Rating of
perceived exertion (RPE) score was higher in persons with MS than controls for all
walking speeds (p=0.004). A RPE score of 1 indicated “not tired at all” and 10
indicated “so tired I cannot go anymore”. Data are presented as means ± S.D. Note that
the order of trials was: slow, fast, preferred.
Figure 4. Relationship between RPE and energy cost of walking. RPE was
significantly associated with Cwpref and Cwslow, but not Cwfast. Closed
circles=control. Open circles=MS.
Figure 5. Relationship between VAFS and energy cost of walking. There
were no associations between VAFS and Cw at any speed. Closed circles=control.
Open circles=MS.
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Figure 6. Relationship between physical activity and energy cost of
walking. Physical activity was associated with the cost of walking (Cw) at a) slow
(Cwslow) and c) fast (Cwfast) speeds, but not at b) preferred speed (Cwpref). Closed
circles=control. Open circles=MS.
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Figure 1. Energy cost of walking at 3 speeds
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Figure 2. Acute symptomatic fatigue at 3 walking speeds
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Figure 3. Ratings of perceived exertion at 3 walking speeds
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Figure 4. Relationship between RPE and energy cost of walking
a)

0.40
0.35

Cwslow (mL·kg-1·m-1)

0.30
0.25
0.20

r=0.57, p=0.006

0.15
0.10
0.05
0.00
0.30

b)

Cwpref (mL·kg-1·m-1)

0.25

0.20

0.15

0.10
r=0.41, p=0.05
0.05

0.00

c)

0.18
0.16

Cwfast (mL·kg-1·m-1)

0.14
0.12
0.10
r=0.26, p=0.22

0.08
0.06
0.04
0.02
0.00
1

2

3

4

5

6

RPE

130

7

8

9

10

Figure 5. Relationship between VAFS and energy cost of walking
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Figure 6. Relationship between physical activity and energy cost of walking
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APPENDIX B
LIST OF MEDICATIONS
Medication

Description

Albeuterol
Amantadine
Amoxicilin
Aricept
Aspirin
Avonex
Baclofen
Botox
Celexa
Cellcept
Claritin
Copaxone
Detrol-LA
DHEA
Diltiazem
Enablex
Flexeril
Fluoxetine
Gabapentin
Hydrochlorothiazide
Imitrex
IV steroid treatment
Klonopin
Lexapro
Lipitor
Lisinopril
Methotrexate
Naltrexone
Neurotin
Nitrofurantoin
Oxytrol
Paroxetine
Prilosec
Provigil
Rebif
Ritalin
Rituxan IV infusion
simvastatin
Synthroid

bronchodilator
anti-viral agent
antibiotic
reversible inhibitor of acetylcholinesterase
anti-inflammatory
Immuno-modulator
muscle relaxant and anti-spastic agent
blocks nerve activity in muscle
anti-depressant
immunosuppressive agent
anti-histamine agent
reduce the frequency of relapses
treats symptoms of overactive bladder
Precursor to sex hormones
anti-hypertensive agent; Ca+-channel blocker
treats symptoms of overactive bladder
muscle relaxant
anti-depressant
anti-epileptic agent
anti-hypertensive agent; diuretic
treat migraines
anti-inflammatory treatment to treat MS relapse
anti-epileptic agent
anti-depressant
cholesterol-lowering agent
anti-hypertensive agent; ACE inhibitor
anti-cancer agent
narcotic drug that blocks the effects of other narcotics
anti-epileptic agent
antibiotic
treats symptoms of overactive bladder
anti-depressant
treats symptoms of gastroesophageal reflux disease
promotes wakefulness
immuno-modulator agent
mild CNS stimulant; improves attention
Monoclonal antibody
cholesterol-lowering agent
treats hypothyroidism
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Trazadone
Unithroid
Vesicare
Vitamin D
Wellbutrin
Xanax
Zoloft

anti-depressant
treats hypothyroidism
treats symptoms of overactive bladder
vitamin D supplement
anti-depressant
treats anxiety and panic disorder
anti-depressant
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APPENDIX C
ASSOCIATIONS BETWEEN ISOMETRIC TORQUE, DYNAMIC POWER,
AND PHYSICAL FUNCTION
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APPENDIX D
COMPARISONS OF NEUROMUSCULAR VARIABLES BETWEEN NONSPASTIC AND PERSONS WITH SPASTICITY

Variable

Non-spastic

With spasticity

p value

Peak Isometric Torque (Nm)

107 ± 31

109 ± 30

0.91

Peak Power (W)

223 ± 71

204 ± 82

0.51

mCSA (cm2)

44.7 ± 9.1

42.3 ± 4.9

0.52

Specific Strength (Nm·cm-2)

2.41 ± 0.52

2.56 ± 0.46

0.58

Specific Power (W·cm-2)

4.98 ± 1.18

4.79 ± 1.57

0.82

maxMUDR (pps)

20.2 ± 5.8

27.2 ± 9.7

0.19

Stimulated RFD (% peak force·ms-1)

1.10 ± 0.36

1.24 ± 0.46

0.58

Voluntary-to-simulated RFD*100 (%)

58.1 ± 20.0

58.9 ± 26.3

0.95

mCSA, fat-free muscle cross-sectional area; maxMUDR, maximal motor unit discharge
rate; RFD, maximal rate of force development.
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APPENDIX E
ASSOCIATIONS BETWEEN SPASTICITY AND PHYSICAL FUNCTION IN
PERSONS WITH MS
y = non-spastic

○ = persons with spasticity
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APPENDIX F
ANCILLARY MEASURES TO CHAPTER 5


To further characterize contractile function, the maximal rate of force relaxation (%
peak force·ms-1) was determined from the first derivative of the torque trace. The
maximal rate of force relaxation was slower in persons with MS (-0.71 ± 0.22 %
peak force·ms-1) compared with controls (-1.05 ± 0.32 % peak force·ms-1,
p=0.0005). These results suggest slowing of calcium re-sequestration to the
sarcoplasmic reticulum in persons with MS compared with controls.



To examine maxMUDR at submaximal intensities, participants were asked to
perform three 50% MVICs (4-5 s duration), with 2 min of rest between trials.
Additional 50% MVIC trials were performed if there were less than 3 trials with
clear recordings. A total of 138 motor units were identified (72 for controls and 66
for MS) at 50% MVIC. Three participants (2 controls, 1 MS) were unable to
perform the intramuscular EMG protocol at 50% MVIC due to non-significant
adverse event (e.g. feeling faint). Average torque achieved when asked to perform
50% MVIC was 50 ± 3 % for both controls and MS during MUDR recordings.
Lower maxMUDR at 50% MVIC were observed in persons with MS (16.0 ± 4.6
pps) compared with controls (20.4 ± 5.9 pps, p=0.04). These results agree with
Dorfman et al. (33), who observed lower maxMUDR at submaximal intensity
contractions in persons with MS compared with controls.



We also measured mean MUDR, which was calculated by averaging all interpulse
intervals of a given motor unit during the plateau phase of each contraction, at 100%
and 50% MVIC. There was no difference in mean MUDR at 100% MVIC across
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groups (controls: 18.6 ± 5.1 pps, MS: 16.3 ± 5.7 pps, p=0.24). At 50% MVIC,
lower mean MUDR were observed in persons with MS (10.8 ± 2.0 pps) compared
with controls (13.8 ± 3.8 pps, p=0.02).


We indirectly compared motor unit recruitment strategies by taking the ratio of
MUDR between 100% and 50% MVIC for each participant. There were no
differences across groups in the ratio of maximal (controls: 1.37 ± 1.38, and MS:
1.38 ± 0.23, p=0.87) and mean (controls: 1.33 ± 0.19, MS: 1.46 ± 0.32, p=0.23)
MUDR at 100% and 50% MVIC.
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APPENDIX G
TABLE OF UNIT CONVERSIONS
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APPENDIX H
PARTICIPANT FORMS
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INFORMED CONSENT DOCUMENT
University of Massachusetts
Amherst, MA 01003
Project Title: Mechanisms of Muscle Weakness in Persons with Multiple Sclerosis

Principal Investigator:
Co-Investigators:

Linda Chung, M.S.
Jane Kent-Braun, Ph.D., Richard van Emmerik, Ph.D.

Your written informed consent is required before you can participate in this project.
Please read this document carefully and then sign your name on the last page if you
agree to participate. This document is in accordance with the General Policy on the
Rights and Welfare of Human Subjects, as approved by the Faculty Senate of the
University of Massachusetts.
Purpose: To systematically determine the causes of reduced muscle strength and
power, and how it impacts energy expenditure, physical function and symptomatic
fatigue in persons with MS.
Eligibility: To participate in this study, you must
1) be between the ages of 30 and 60 years
2) be free from metabolic, non-MS neurologic, cardiovascular or other major
disease
3) not be taking any medications (other than for MS) that may affect muscle
function (i.e., beta blockers, sedatives, anti-cholesterol medications, etc.)
4) have a visual acuity of 20/200 or better
5) participate in less than three 30-minute structured exercise sessions per week
6) not be pregnant
7) not have cognitive impairment or a mental disorder that precludes following
instructions
8) not have significant arthritis in the lower extremities
9) have no history of breathing difficulties, cramping, light-headedness or other
symptoms of exertion
10) not be a smoker
11) not have oculomotor and/or cerebellar disorders
12) have no history of claustrophobia
13) not have pieces of metal in your body (such as fragment(s) in the eye,
aneurysm clips, ear implants, spinal nerve stimulator, and pacemaker)
All persons with MS must also have clinically verified MS (any subtype).
Procedures: Prior to your participation in this study, you will be screened by telephone
interview for general health status, medical history, current medications and usual
physical activity habits. If you are qualified and agree to participate in the study, the
following table outlines the measures we’ll be making in each visit. Each visit will be
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separated by 3 to 7 days. A more detailed explanation of each of the measures are
described below the table.
Visit #
1

3

Measures
Questionnaires
Anthropometrics
Blood pressure
Physical function
Familiarization of dynamometer protocols
Activity monitor instructions
 Dynamometer protocols on both legs
 Passive resistance
 Isometric contractions
 Isovelocity contractions
 Electrical stimulation
Intramuscular electromyography on both legs

4

MRI of both legs

2








Location
Muscle Physiology
Lab at UMassAmherst

Duration
2.5 hours

Muscle Physiology
Lab at UMassAmherst

2.5 hours

Exercise
Neuroscience Lab
at UMass-Amherst
MRI Center
Cooley Dickinson
Hospital in
Amherst

1.5 hours
1.5 hours

Questionnaires. You will be asked to complete the following questionnaires: medical
history, self-reported expanded disability status score, modified fatigue impact
scale, visual analog fatigue scale, spasticity scale, and physical activity readiness.
You will also be asked to complete the magnetic resonance safety form to determine
your eligibility to enter the MRI room.
Anthropometrics. We will measure your height, weight, and length of your lower limb.
Blood pressure. We will measure your blood pressure at the arm while you are lying
down on a bed.
Physical Function. Your level of physical function will be measured using the
following performance tests, which the investigator will demonstrate for you:
 Metabolic Rate While Walking
- We will measure how much energy you expend while walking
at 3 different speeds. To do this, we will first measure your
resting metabolic rate (following an overnight fast). You will
lay on a bed with a ventilated hood placed over your head for
20 minutes. The ventilated hood will measure the difference in
oxygen between the air you breathe in and the air you breathe
out during normal breathing.
- Next, you will be asked to breathe through a mouthpiece, which
will be connected to an indirect calorimeter via a hose, so that
we can measure your metabolic rate while you are walking.
You will be asked to walk on a treadmill at a self-selected
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pace, and at slow and fast speeds, for 4 minutes each. You will
be given 5-10 minutes of seated rest between walking tests.
 Walking speed
- You will be asked to walk 25 feet twice, once at a self-selected
pace and once at a brisk pace.
 Leg function
- To assess your leg strength, we will ask you to perform rapid
chair rises 5 times
 Foot tap speed
- You will be asked to perform rapid foot taps for 10 seconds for
each foot.

Familiarization to dynamometer protocols. A dynamometer is an instrument that lets
us measure the force your muscles produce while your leg is static, or moving at a fixed
speed. You will be seated in a chair with your upper body secured with seat belt straps.
Your lower leg will be secured to a rotating apparatus using Velcro. Using one of your
legs, we will then familiarize you with the contraction protocols that you will perform
(see Dynamometer Protocols below), so that you are comfortable with the procedures.
Activity Monitor. At the end of your Visit 1, you will be asked to wear an activity
monitor around your waist for 7 days during waking hours. The activity monitor is
a small plastic device (about the size of a pager) that measures vertical
accelerations, and will give us an idea of your daily physical activity level. You
will also be asked to keep a simple diary of your physical activities. You will return
the activity monitor and diary on your next visit.
Dynamometer protocols. Prior to being seated on the dynamometer, you will be asked
to warm-up your leg muscles by cycling on a recumbent bike for 2 minutes without
any resistance. Following this warm-up, we will tape small electromyography
electrodes to the skin on the front and back sides of your thigh, as well as on the
bony part of your knee. Surface electromyography electrodes will measure the
electrical activity from your muscles. Once you are seated and secured to the
dynamometer (see Familiarization of Dynamometer Protocols), you will perform the
following protocols:
- Passive resistance. While you are relaxed, the dynamometer will extend and flex
your knee over a set range of motion at different speeds. The data obtained from
this protocol will give us information about spasticity, which is defined as
increased muscle tone or stiffness due to a hyper-excitable reflex.
- Isometric contractions. You will perform 3 to 4 static, maximal contractions of
your quadriceps muscles (front of the thigh). Each contraction will last no
longer than 5 seconds. You will repeat this with the hamstring muscles (back of
the thigh).
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- Isovelocity contractions. You will perform maximal voluntary contractions by
extending your knee against different speeds of resistance. Your leg will move
during muscle contraction, but the movement of your leg will be limited to a
fixed range.
- Electrical stimulation. In addition to the surface electromyography electrodes, 2
flexible stimulating pads will be placed over your thigh. These pads are
designed to stimulate your muscle to contract without any effort on your part,
which will give us information about your muscle’s function. We will set the
intensity of the stimulation to produce a force level that is 50% of your
maximum voluntary strength. Once the intensity is set, we will give you a burst
of stimuli that lasts 1 second while your leg remains in a static position and you
stay relaxed. We will apply the same burst 2 more times, with 2 minutes of rest
between each burst.
Intramuscular Electromyography. Like surface electromyography, electrical activity
from your muscle will be measured using a small, sterilized needle electrode placed
directly into your muscle. It will remain there for ~30-40 min. This will provide us
precise information about your muscle activation. Electrical signals during
submaximal and maximal voluntary isometric contractions will be recorded. To
obtain clear electrical signals, slight adjustments of the electrode will be made. This
procedure will be performed in the Exercise Neuroscience Lab, just down the hall
from the Muscle Physiology Lab, and will be done in both legs.
MRI. An MRI of your thighs will be taken at the Cooley Dickinson Hospital MRI
Center on University Drive in Amherst. We will provide transportation to Cooley
Dickinson for you, if you wish. You will be asked to complete a brief medical
history form and Magnetic Materials Safety questionnaire to ensure that there are no
magnetic materials in your body. After we ensure that you are free of magnetic
objects, you will be taken into the MRI room, where you will lie on the MRI bed
and have your leg centered inside a circular coil. This coil, which is shaped like a
small tube, will allow us to obtain information about the size and shape of your
muscles, using radio waves and a superconducting magnet. To protect your hearing
during the imaging, you will be given earplugs or headphones to wear. After you
are positioned comfortably, we will slide the MRI bed into the scanner. We will
then collect anatomical images of your leg. While acquiring images, the table may
shake slightly, and you will hear loud knocking noises. This is a normal part of the
imaging procedure. This procedure will take approximately 30 minutes per leg and
both legs will be imaged.
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Possible Risks and Discomforts: The following risks and discomforts are associated
with the procedures described above.

Isometric and isovelocity contractions. Although we will try to give you enough rest in
between contractions, you may develop some muscle fatigue. You may also
experience some soreness following the voluntary contractions, which may come
about immediately or later in the day. The soreness is normal and will subside in a
couple of days. The soreness should not affect your normal daily activities.
Electrical stimulation. Although stimulation is brief, you may experience some
discomfort.
Intramuscular Electromyography. Insertion of the electrode into the muscle will be
uncomfortable. However, the discomfort should dissipate after about a minute. If
the discomfort persists, then slight adjustments can be made to relieve any
discomfort. Like any foreign body, the needle electrode poses a risk for infection.
This electrode is thoroughly gas-sterilized before it is used. In our experience, no
individual has ever experienced adverse consequences from this electrode. It is
possible that you may experience nausea, feel faint, and, though extremely rare, lose
consciousness. In the event of such experiences, the session will be terminated and
all proper measures will be made to ensure your comfort and safety.
MRI. When in the magnet, there is a very small possibility that the magnetic field will
pull an iron-containing object into the magnet, which might result in physical injury.
However, precautions have been taken to prevent such an event from happening; all
subjects will walk through a metal detector to ensure that no loose metal objects,
like pocketknives or key chains, are brought into the magnet room. If you have a
piece of metal in your body, such as fragment in your eye, aneurysm clips, ear
implants, spinal nerve stimulators, or a pacemaker, you will not be allowed into the
magnet room and cannot participate in this study. One potential hazard of having an
MRI is heating of the body due to the radio waves that we use. However, the MRI
machine has safety devices that will prevent this from happening. Women, who are
pregnant, or trying to conceive, are discouraged from participating in MRI studies
due to the potential risks associated with this procedure. Your head will be at the
opening of the magnet; however, you may be bothered by feelings of claustrophobia
or by the load noise during the MRI session. Temporary hearing loss has been
reported from this loud noise, so you will be asked to wear earplugs or headphones.
If at any time you feel too claustrophobic or too uncomfortable to continue, the MRI
session will be stopped immediately.
Confidentiality: Your identity and records will be kept confidential. While results
from this study will be shared with other researchers, no individual identities will be
used in any reports or publications resulting from this study.
In Case of Injury: In the unlikely event of injury, resulting directly from participation
in this study, we will do everything we can to assist you in seeking medical treatment.
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The University of Massachusetts will not provide compensation for medical treatment
you obtain.
Benefits: You will receive no direct benefit from participating in this study. Any
information that is obtained from this study will be made available to your physician,
upon request. The purpose of this study is to provide the investigators with information
that will help us understand the mechanisms of muscle weakness in persons with MS.
This study may provide an evidence-based rationale for specially-designed exercise
therapies improving muscle strength and power in persons with MS.
Costs and Reimbursement: You will receive $100 for completing this study. A check
will be mailed to your home approximately six weeks after your last visit. In the event
that you do not complete the study, partial compensation will be provided as follows:
$10 for visit 1 only, $30 each for visits 2, 3, and 4. This study is supported by an
ACSM Foundation Research Grant (FRG) from the American College of Sports
Medicine Foundation and the National Multiple Sclerosis Society.
Withdrawal of Participation: Participation in this research is voluntary. You have
the right to withdraw from this study at any time, for any reason.
Information: You are encouraged to ask questions about the study. The investigators
will attempt to answer all of your questions to the best of their knowledge. The
investigators fully intend to conduct the study with your best interest, safety and
comfort in mind. Please address any questions regarding the study to Linda Chung,
M.S. (413) 545-5305, Dr. Jane Kent-Braun, Ph.D. (413) 545-9477, or Dr. Richard van
Emmerik Ph.D. (413) 545-0325. If you would like to speak with someone not directly
involved in the research study, you may contact the Human Research Protection Office
at the University of Massachusetts via email at humansubject@ora.umass.edu;
telephone (413) 545-3428; or mail at the Human Research Protection Office, Research
Administration Building, University of Massachusetts Amherst, 70 Butterfield Terrace,
Amherst, MA 01003-9242.

Participant’s Name

Signature

Address

Date

Phone Number

Linda Chung, M.S.

Jane Kent-Braun, Ph.D. or Richard van Emmerik, Ph.D.
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Medical History Form
Please fill out and sign in ink. This record is confidential.
Name (print):___________________________

Date:__________________

Signature:_________________________________
Medical History
Are you taking any prescribed or over-the-counter medications? Please include
vitamins, herbs or other dietary supplements. If yes, please list dose, frequency and
duration of use.
______________________________________________________________________
______________________________________________________________________
Have you ever been told by a physician that you should not exercise?
Yes_____No_____
If yes, please explain: ____________________________________________________
______________________________________________________________________
______________________________________________________________________
Do you or have you EVER had any of the following problems? Check if YES and
provide details below.
____Heart disease/rheumatic fever
____Thyroid disorder
____High blood pressure
____Claustrophobia
____Elevated cholesterol
____Anemia
____Epilepsy or seizure disorder
____Diabetes
____Blurred or double vision
____Orthopedic or joint problems (e.g., arthritis)
____Shortness of breath or difficulty in breathing
____Phlebitis, blood clots, varicose veins, peripheral vascular disease

____Asthma
____Allergies
____Stroke
____Dizziness

Details:________________________________________________________________
______________________________________________________________________
Lifestyle
Do you smoke cigarettes?
Do you drink alcohol?
Do you exercise regularly?
Have you had surgery?

Yes____
No____
Yes____
No____
Yes____
No____
If yes, number of times per week_____
Yes____
No____
If yes, when was this?___________________

Is there any other information or concern you have that you feel we should know about
before you participate in the study? If so, please explain.
______________________________________________________________________
______________________________________________________________________
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PHYSICAL ACTIVITY READINESS QUESTIONNAIRE
1. Has a doctor ever said you have a heart condition and recommended only
medically supervised activity?
Yes____
No____
2. Do you have chest pain brought on by physical activity?
Yes____

No____

3. Have you developed chest pain in the last month?
Yes____

No____

4. Do you tend to lose consciousness or fall over as a result of dizziness?
Yes____

No____

5. Do you have a bone or joint problems that could be aggravated by the proposed
physical activity?
Yes____

No____

6. Has a doctor ever recommended medication for your blood pressure or a heart
condition?
Yes____

No____

7. Are you aware through your own experience, or a doctor’s advice, of any other
physical reason against your exercising without medical supervision?
Yes____

No____

NOTE: If you have a temporary illness, such as a common cold, or are not feeling well
at this time – POSTPONE.

NAME_______________________________
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DATE_________________
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